Isocitrate Dehydrogenase 1 (IDH1) is a soluble, cytoclic enzyme involved in the TCA metablic cycle. The most notable mutation in this enzyme, R132H, is clinically indicated in the majority of astrocytomas and oligodendroglial tumours, with the mutation being associated with more favourable prognosis and increased survival in those patients. IDH1 R132H is also useful in the differential diagnosis between anaplastic glioma and glioblastoma.
HMB-45 is specific for an antigen present in immature melanosomes, cutaneous melanocytes, and prenatal and infantile retinal pigment epithelium cells. It is therefore effective for identifying malignant melanoma, and differentiating metastatic amelanotic melanoma from a number of conditions where the discrimination is often extremely difficult, including large cell lymphomas, sarcomas, spindle cell carcinomas, and various types of mesenchymal neoplasms. This antibody can also differentiate between junctional nevus and intradermal nevus cells, and between fetal or neonatal melanocytes and normal adult melanocytes.
HMB-45 is specific for an antigen present in immature melanosomes, cutaneous melanocytes, and prenatal and infantile retinal pigment epithelium cells. It is therefore effective for identifying malignant melanoma, and differentiating metastatic amelanotic melanoma from a number of conditions where the discrimination is often extremely difficult, including large cell lymphomas, sarcomas, spindle cell carcinomas, and various types of mesenchymal neoplasms. This antibody can also differentiate between junctional nevus and intradermal nevus cells, and between fetal or neonatal melanocytes and normal adult melanocytes.
HMB-45 is specific for an antigen present in immature melanosomes, cutaneous melanocytes, and prenatal and infantile retinal pigment epithelium cells. It is therefore effective for identifying malignant melanoma, and differentiating metastatic amelanotic melanoma from a number of conditions where the discrimination is often extremely difficult, including large cell lymphomas, sarcomas, spindle cell carcinomas, and various types of mesenchymal neoplasms. This antibody can also differentiate between junctional nevus and intradermal nevus cells, and between fetal or neonatal melanocytes and normal adult melanocytes.
HMB-45 is specific for an antigen present in immature melanosomes, cutaneous melanocytes, and prenatal and infantile retinal pigment epithelium cells. It is therefore effective for identifying malignant melanoma, and differentiating metastatic amelanotic melanoma from a number of conditions where the discrimination is often extremely difficult, including large cell lymphomas, sarcomas, spindle cell carcinomas, and various types of mesenchymal neoplasms. This antibody can also differentiate between junctional nevus and intradermal nevus cells, and between fetal or neonatal melanocytes and normal adult melanocytes.
The HER2/neu (c-erbB-2) proto-oncogene is a transmembrane receptor tyrosine kinase that is clinically indicated in a number of carcinomas. Overexpression of the c-erbB-2 protein has been associated with ductal breast cancer, as well as pulmonary and gastric adenocarcinomas. A correlation between HER2 and p53 has also been documented, as overexpression of both proteins has been associated with early invasion and metastasis in bladder cancer.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
The HER2/neu (c-erbB-2) proto-oncogene is a transmembrane receptor tyrosine kinase that is clinically indicated in a number of carcinomas. Overexpression of the c-erbB-2 protein has been associated with ductal breast cancer, as well as pulmonary and gastric adenocarcinomas. A correlation between HER2 and p53 has also been documented, as overexpression of both proteins has been associated with early invasion and metastasis in bladder cancer.
Product Type:
Primary Antibody
Antibody Type:
Polyclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC012
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Breast Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
The HER2/neu (c-erbB-2) proto-oncogene is a transmembrane receptor tyrosine kinase that is clinically indicated in a number of carcinomas. Overexpression of the c-erbB-2 protein has been associated with ductal breast cancer, as well as pulmonary and gastric adenocarcinomas. A correlation between HER2 and p53 has also been documented, as overexpression of both proteins has been associated with early invasion and metastasis in bladder cancer.
Product Type:
Primary Antibody
Antibody Type:
Polyclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC012
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Breast Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
The HER2/neu (c-erbB-2) proto-oncogene is a transmembrane receptor tyrosine kinase that is clinically indicated in a number of carcinomas. Overexpression of the c-erbB-2 protein has been associated with ductal breast cancer, as well as pulmonary and gastric adenocarcinomas. A correlation between HER2 and p53 has also been documented, as overexpression of both proteins has been associated with early invasion and metastasis in bladder cancer.
Product Type:
Primary Antibody
Antibody Type:
Polyclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC012
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Breast Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
The HER2/neu (c-erbB-2) proto-oncogene is a transmembrane receptor tyrosine kinase that is clinically indicated in a number of carcinomas. Overexpression of the c-erbB-2 protein has been associated with ductal breast cancer, as well as pulmonary and gastric adenocarcinomas. A correlation between HER2 and p53 has also been documented, as overexpression of both proteins has been associated with early invasion and metastasis in bladder cancer.
The HER2/neu (c-erbB-2) proto-oncogene is a transmembrane receptor tyrosine kinase that is clinically indicated in a number of carcinomas. Overexpression of the c-erbB-2 protein has been associated with ductal breast cancer, as well as pulmonary and gastric adenocarcinomas. A correlation between HER2 and p53 has also been documented, as overexpression of both proteins has been associated with early invasion and metastasis in bladder cancer.
The HER2/neu (c-erbB-2) proto-oncogene is a transmembrane receptor tyrosine kinase that is clinically indicated in a number of carcinomas. Overexpression of the c-erbB-2 protein has been associated with ductal breast cancer, as well as pulmonary and gastric adenocarcinomas. A correlation between HER2 and p53 has also been documented, as overexpression of both proteins has been associated with early invasion and metastasis in bladder cancer.
The HER2/neu (c-erbB-2) proto-oncogene is a transmembrane receptor tyrosine kinase that is clinically indicated in a number of carcinomas. Overexpression of the c-erbB-2 protein has been associated with ductal breast cancer, as well as pulmonary and gastric adenocarcinomas. A correlation between HER2 and p53 has also been documented, as overexpression of both proteins has been associated with early invasion and metastasis in bladder cancer.
The HER2/neu (c-erbB-2) proto-oncogene is a transmembrane receptor tyrosine kinase that is clinically indicated in a number of carcinomas. Overexpression of the c-erbB-2 protein has been associated with ductal breast cancer, as well as pulmonary and gastric adenocarcinomas. A correlation between HER2 and p53 has also been documented, as overexpression of both proteins has been associated with early invasion and metastasis in bladder cancer.
The HER2/neu (c-erbB-2) proto-oncogene is a transmembrane receptor tyrosine kinase that is clinically indicated in a number of carcinomas. Overexpression of the c-erbB-2 protein has been associated with ductal breast cancer, as well as pulmonary and gastric adenocarcinomas. A correlation between HER2 and p53 has also been documented, as overexpression of both proteins has been associated with early invasion and metastasis in bladder cancer.
The HER2/neu (c-erbB-2) proto-oncogene is a transmembrane receptor tyrosine kinase that is clinically indicated in a number of carcinomas. Overexpression of the c-erbB-2 protein has been associated with ductal breast cancer, as well as pulmonary and gastric adenocarcinomas. A correlation between HER2 and p53 has also been documented, as overexpression of both proteins has been associated with early invasion and metastasis in bladder cancer.
The HER2/neu (c-erbB-2) proto-oncogene is a transmembrane receptor tyrosine kinase that is clinically indicated in a number of carcinomas. Overexpression of the c-erbB-2 protein has been associated with ductal breast cancer, as well as pulmonary and gastric adenocarcinomas. A correlation between HER2 and p53 has also been documented, as overexpression of both proteins has been associated with early invasion and metastasis in bladder cancer.
Hepatocyte Specific Antigen, also known as Hep-Par1, has proven to be strongly useful in the detection of both benign and malignant liver-derived tissues, and associated tumours such as hepatoblastoma and hepatocellular carcinoma (HCC). The pathological diagnosis of HCC is often difficult as it shares histological and cytological features with adenoid cystic carcinoma, renal cell carcinoma, adenocarcinoma, and cholangiocarcinoma. Hep-Par1 is indicated as an effective marker to distinguish between these mimics, and therefore aids in the differential diagnosis of HCC.
Hepatocyte Specific Antigen, also known as Hep-Par1, has proven to be strongly useful in the detection of both benign and malignant liver-derived tissues, and associated tumours such as hepatoblastoma and hepatocellular carcinoma (HCC). The pathological diagnosis of HCC is often difficult as it shares histological and cytological features with adenoid cystic carcinoma, renal cell carcinoma, adenocarcinoma, and cholangiocarcinoma. Hep-Par1 is indicated as an effective marker to distinguish between these mimics, and therefore aids in the differential diagnosis of HCC.
Hepatocyte Specific Antigen, also known as Hep-Par1, has proven to be strongly useful in the detection of both benign and malignant liver-derived tissues, and associated tumours such as hepatoblastoma and hepatocellular carcinoma (HCC). The pathological diagnosis of HCC is often difficult as it shares histological and cytological features with adenoid cystic carcinoma, renal cell carcinoma, adenocarcinoma, and cholangiocarcinoma. Hep-Par1 is indicated as an effective marker to distinguish between these mimics, and therefore aids in the differential diagnosis of HCC.
Hepatocyte Specific Antigen, also known as Hep-Par1, has proven to be strongly useful in the detection of both benign and malignant liver-derived tissues, and associated tumours such as hepatoblastoma and hepatocellular carcinoma (HCC). The pathological diagnosis of HCC is often difficult as it shares histological and cytological features with adenoid cystic carcinoma, renal cell carcinoma, adenocarcinoma, and cholangiocarcinoma. Hep-Par1 is indicated as an effective marker to distinguish between these mimics, and therefore aids in the differential diagnosis of HCC.
The Human Equilibrative Nucleoside Transporter 1 (hENT1) mediates the cellular uptake of physiologic nucleosides, including adenosine, as well as many anti-cancer drugs including gemcitabine, cytarabine, and decitabine. Deficiency of hENT1 can lead to resistance of such drugs, and the abundance of hENT1 protein in the plasma membrane is a major indicator of the efficiency and clinical outcome of these anti-cancer nucleosides.
The Human Equilibrative Nucleoside Transporter 1 (hENT1) mediates the cellular uptake of physiologic nucleosides, including adenosine, as well as many anti-cancer drugs including gemcitabine, cytarabine, and decitabine. Deficiency of hENT1 can lead to resistance of such drugs, and the abundance of hENT1 protein in the plasma membrane is a major indicator of the efficiency and clinical outcome of these anti-cancer nucleosides.
The Human Equilibrative Nucleoside Transporter 1 (hENT1) mediates the cellular uptake of physiologic nucleosides, including adenosine, as well as many anti-cancer drugs including gemcitabine, cytarabine, and decitabine. Deficiency of hENT1 can lead to resistance of such drugs, and the abundance of hENT1 protein in the plasma membrane is a major indicator of the efficiency and clinical outcome of these anti-cancer nucleosides.
The Human Equilibrative Nucleoside Transporter 1 (hENT1) mediates the cellular uptake of physiologic nucleosides, including adenosine, as well as many anti-cancer drugs including gemcitabine, cytarabine, and decitabine. Deficiency of hENT1 can lead to resistance of such drugs, and the abundance of hENT1 protein in the plasma membrane is a major indicator of the efficiency and clinical outcome of these anti-cancer nucleosides.
<em>Helicobacter pylori</em> are spiral-shaped, gram-negative bacteria that inhabit the mucosal lining of the gastric epithelium. Infection with <em>H. pylori</em> is strongly associated with many gastroduodenal diseases, including intestinal-type carcinomas, peptic and gastric ulcers, and chronic gastritis. There is evidence linking these bacteria to gastric and mucosa-associated lymphoid tissue lymphomas, and <em>H. pylori</em> has also been indicated as a risk factor for colorectal polyps in children.
<em>Helicobacter pylori</em> are spiral-shaped, gram-negative bacteria that inhabit the mucosal lining of the gastric epithelium. Infection with <em>H. pylori</em> is strongly associated with many gastroduodenal diseases, including intestinal-type carcinomas, peptic and gastric ulcers, and chronic gastritis. There is evidence linking these bacteria to gastric and mucosa-associated lymphoid tissue lymphomas, and <em>H. pylori</em> has also been indicated as a risk factor for colorectal polyps in children.
<em>Helicobacter pylori</em> are spiral-shaped, gram-negative bacteria that inhabit the mucosal lining of the gastric epithelium. Infection with <em>H. pylori</em> is strongly associated with many gastroduodenal diseases, including intestinal-type carcinomas, peptic and gastric ulcers, and chronic gastritis. There is evidence linking these bacteria to gastric and mucosa-associated lymphoid tissue lymphomas, and <em>H. pylori</em> has also been indicated as a risk factor for colorectal polyps in children.
<em>Helicobacter pylori</em> are spiral-shaped, gram-negative bacteria that inhabit the mucosal lining of the gastric epithelium. Infection with <em>H. pylori</em> is strongly associated with many gastroduodenal diseases, including intestinal-type carcinomas, peptic and gastric ulcers, and chronic gastritis. There is evidence linking these bacteria to gastric and mucosa-associated lymphoid tissue lymphomas, and <em>H. pylori</em> has also been indicated as a risk factor for colorectal polyps in children.
Human Chorionic Gonadotropin (hCG) is a glycoprotein hormone produced by the trophoblastic cells of the placenta after conception. Anti-hCG is useful for identifying trophoblastic tumours, such as choriocarcinoma. hCG is also a marker for non-trophoblastic tumours such as large cell carcinoma and lung adenocarcinoma.
Human Chorionic Gonadotropin (hCG) is a glycoprotein hormone produced by the trophoblastic cells of the placenta after conception. Anti-hCG is useful for identifying trophoblastic tumours, such as choriocarcinoma. hCG is also a marker for non-trophoblastic tumours such as large cell carcinoma and lung adenocarcinoma.
Human Chorionic Gonadotropin (hCG) is a glycoprotein hormone produced by the trophoblastic cells of the placenta after conception. Anti-hCG is useful for identifying trophoblastic tumours, such as choriocarcinoma. hCG is also a marker for non-trophoblastic tumours such as large cell carcinoma and lung adenocarcinoma.
Human Chorionic Gonadotropin (hCG) is a glycoprotein hormone produced by the trophoblastic cells of the placenta after conception. Anti-hCG is useful for identifying trophoblastic tumours, such as choriocarcinoma. hCG is also a marker for non-trophoblastic tumours such as large cell carcinoma and lung adenocarcinoma.
Hepatitis B surface antigen (HBsAg) contains the large (L), middle (M), and small (S) surface proteins of the Hepatitis-B-Virus (HBV). It is the surface antigen of HBV, indicating current Hepatitis B infection. The body produces antibodies to HBsAg as part of the normal immune response to infection. Immunohistochemical staining for HBsAg in liver tissue is useful for the detection of HBV.
Hepatitis B surface antigen (HBsAg) contains the large (L), middle (M), and small (S) surface proteins of the Hepatitis-B-Virus (HBV). It is the surface antigen of HBV, indicating current Hepatitis B infection. The body produces antibodies to HBsAg as part of the normal immune response to infection. Immunohistochemical staining for HBsAg in liver tissue is useful for the detection of HBV.
Hepatitis B surface antigen (HBsAg) contains the large (L), middle (M), and small (S) surface proteins of the Hepatitis-B-Virus (HBV). It is the surface antigen of HBV, indicating current Hepatitis B infection. The body produces antibodies to HBsAg as part of the normal immune response to infection. Immunohistochemical staining for HBsAg in liver tissue is useful for the detection of HBV.
Hepatitis B surface antigen (HBsAg) contains the large (L), middle (M), and small (S) surface proteins of the Hepatitis-B-Virus (HBV). It is the surface antigen of HBV, indicating current Hepatitis B infection. The body produces antibodies to HBsAg as part of the normal immune response to infection. Immunohistochemical staining for HBsAg in liver tissue is useful for the detection of HBV.
Anti-Hairy Cell Leukemia stains various B-cells in the follicular mantle zone and virtually all cases of hairy cell leukemia. It also stains some high grade B-cell lymphomas.
Anti-Hairy Cell Leukemia stains various B-cells in the follicular mantle zone and virtually all cases of hairy cell leukemia. It also stains some high grade B-cell lymphomas.
Anti-Hairy Cell Leukemia stains various B-cells in the follicular mantle zone and virtually all cases of hairy cell leukemia. It also stains some high grade B-cell lymphomas.
Anti-Hairy Cell Leukemia stains various B-cells in the follicular mantle zone and virtually all cases of hairy cell leukemia. It also stains some high grade B-cell lymphomas.
Growth Hormone (GH or hGH) is a peptidic hormone produced by somatotrophs of the anterior pituitary gland. Anti-Growth Hormone stains somatotrophs in normal pituitary tissues, and is useful in identifying pituitary tumours and understanding pituitary disease or acromegaly. Studies have also found Anti-GH to stain non-pituitary cells, such as hepatocellular carcinoma and cutaneous lesions.
Growth Hormone (GH or hGH) is a peptidic hormone produced by somatotrophs of the anterior pituitary gland. Anti-Growth Hormone stains somatotrophs in normal pituitary tissues, and is useful in identifying pituitary tumours and understanding pituitary disease or acromegaly. Studies have also found Anti-GH to stain non-pituitary cells, such as hepatocellular carcinoma and cutaneous lesions.
Growth Hormone (GH or hGH) is a peptidic hormone produced by somatotrophs of the anterior pituitary gland. Anti-Growth Hormone stains somatotrophs in normal pituitary tissues, and is useful in identifying pituitary tumours and understanding pituitary disease or acromegaly. Studies have also found Anti-GH to stain non-pituitary cells, such as hepatocellular carcinoma and cutaneous lesions.
Growth Hormone (GH or hGH) is a peptidic hormone produced by somatotrophs of the anterior pituitary gland. Anti-Growth Hormone stains somatotrophs in normal pituitary tissues, and is useful in identifying pituitary tumours and understanding pituitary disease or acromegaly. Studies have also found Anti-GH to stain non-pituitary cells, such as hepatocellular carcinoma and cutaneous lesions.
Glypican-3 (GPC3) is a GPI-anchored proteoglycan involved in cell division and growth regulation. Glypican-3 is a useful tumour marker, and its expression has been shown to be upregulated in hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumours, and Wilms' tumour. Patients with HCC have presented elevated levels of GPC3 in the neoplastic liver tissues and serum, levels which are higher than detected in cirrhotic liver or liver with focal lesions, including those with hepatic adenoma and dysplastic nodules. Glypican-3 is also overexpressed in testicular germ cell tumours of certain subtypes, such as yolk sac tumours and choriocarcinoma, and in embryonal tumours.
Glypican-3 (GPC3) is a GPI-anchored proteoglycan involved in cell division and growth regulation. Glypican-3 is a useful tumour marker, and its expression has been shown to be upregulated in hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumours, and Wilms' tumour. Patients with HCC have presented elevated levels of GPC3 in the neoplastic liver tissues and serum, levels which are higher than detected in cirrhotic liver or liver with focal lesions, including those with hepatic adenoma and dysplastic nodules. Glypican-3 is also overexpressed in testicular germ cell tumours of certain subtypes, such as yolk sac tumours and choriocarcinoma, and in embryonal tumours.
Glypican-3 (GPC3) is a GPI-anchored proteoglycan involved in cell division and growth regulation. Glypican-3 is a useful tumour marker, and its expression has been shown to be upregulated in hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumours, and Wilms' tumour. Patients with HCC have presented elevated levels of GPC3 in the neoplastic liver tissues and serum, levels which are higher than detected in cirrhotic liver or liver with focal lesions, including those with hepatic adenoma and dysplastic nodules. Glypican-3 is also overexpressed in testicular germ cell tumours of certain subtypes, such as yolk sac tumours and choriocarcinoma, and in embryonal tumours.
Glypican-3 (GPC3) is a GPI-anchored proteoglycan involved in cell division and growth regulation. Glypican-3 is a useful tumour marker, and its expression has been shown to be upregulated in hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumours, and Wilms' tumour. Patients with HCC have presented elevated levels of GPC3 in the neoplastic liver tissues and serum, levels which are higher than detected in cirrhotic liver or liver with focal lesions, including those with hepatic adenoma and dysplastic nodules. Glypican-3 is also overexpressed in testicular germ cell tumours of certain subtypes, such as yolk sac tumours and choriocarcinoma, and in embryonal tumours.
Glypican-3 (GPC3) is a GPI-anchored proteoglycan involved in cell division and growth regulation. Glypican-3 is a useful tumour marker, and its expression has been shown to be upregulated in hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumours, and Wilms' tumour. Patients with HCC have presented elevated levels of GPC3 in the neoplastic liver tissues and serum, levels which are higher than detected in cirrhotic liver or liver with focal lesions, including those with hepatic adenoma and dysplastic nodules. Glypican-3 is also overexpressed in testicular germ cell tumours of certain subtypes, such as yolk sac tumours and choriocarcinoma, and in embryonal tumours.
Glypican-3 (GPC3) is a GPI-anchored proteoglycan involved in cell division and growth regulation. Glypican-3 is a useful tumour marker, and its expression has been shown to be upregulated in hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumours, and Wilms' tumour. Patients with HCC have presented elevated levels of GPC3 in the neoplastic liver tissues and serum, levels which are higher than detected in cirrhotic liver or liver with focal lesions, including those with hepatic adenoma and dysplastic nodules. Glypican-3 is also overexpressed in testicular germ cell tumours of certain subtypes, such as yolk sac tumours and choriocarcinoma, and in embryonal tumours.
Glypican-3 (GPC3) is a GPI-anchored proteoglycan involved in cell division and growth regulation. Glypican-3 is a useful tumour marker, and its expression has been shown to be upregulated in hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumours, and Wilms' tumour. Patients with HCC have presented elevated levels of GPC3 in the neoplastic liver tissues and serum, levels which are higher than detected in cirrhotic liver or liver with focal lesions, including those with hepatic adenoma and dysplastic nodules. Glypican-3 is also overexpressed in testicular germ cell tumours of certain subtypes, such as yolk sac tumours and choriocarcinoma, and in embryonal tumours.
Glypican-3 (GPC3) is a GPI-anchored proteoglycan involved in cell division and growth regulation. Glypican-3 is a useful tumour marker, and its expression has been shown to be upregulated in hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumours, and Wilms' tumour. Patients with HCC have presented elevated levels of GPC3 in the neoplastic liver tissues and serum, levels which are higher than detected in cirrhotic liver or liver with focal lesions, including those with hepatic adenoma and dysplastic nodules. Glypican-3 is also overexpressed in testicular germ cell tumours of certain subtypes, such as yolk sac tumours and choriocarcinoma, and in embryonal tumours.
Glycophorin A (GPA) and Glycophorin B (GPB) are erythrocyte blood group determinants that minimize erythrocyte aggregation during the circulation of blood. Anti-Glycophorin A is useful for understanding erythroid cell development and identifying erythroid leukemias.
Glycophorin A (GPA) and Glycophorin B (GPB) are erythrocyte blood group determinants that minimize erythrocyte aggregation during the circulation of blood. Anti-Glycophorin A is useful for understanding erythroid cell development and identifying erythroid leukemias.
Glycophorin A (GPA) and Glycophorin B (GPB) are erythrocyte blood group determinants that minimize erythrocyte aggregation during the circulation of blood. Anti-Glycophorin A is useful for understanding erythroid cell development and identifying erythroid leukemias.
Glycophorin A (GPA) and Glycophorin B (GPB) are erythrocyte blood group determinants that minimize erythrocyte aggregation during the circulation of blood. Anti-Glycophorin A is useful for understanding erythroid cell development and identifying erythroid leukemias.
Glutamine Synthetase (GS-6 or GS) catalyzes the conversion of glutamate and ammonia to glutamine in the liver, and is expressed in pericentral hepatocytes, but not in periportal hepatocytes or in the mid-zonal. Anti-Glutamine Synthetase is useful in some hepatocellular carcinomas and many high grade dysplastic nodules, and therefore may be useful in recognizing these cases. A panel of antibodies against HSP70 (heat shock protein 70), GPC3, and glutamine synthetase is useful for differentiating dysplastic from early malignant hepatocellular nodules in cirrhosis. GS staining of hepatocellular lesions is useful for the differential diagnosis of focal nodular hyperplasia (FNH), hepatic adenoma (HCA), dysplastic nodules, and low grade hepatocellular carcinoma. FNH produces a “map-like” pattern when stained with Anti-Glutamine Synthetase. Conversely, HCA can stain negatively, produce border staining, or stain around the tumour veins.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Glutamine Synthetase (GS-6 or GS) catalyzes the conversion of glutamate and ammonia to glutamine in the liver, and is expressed in pericentral hepatocytes, but not in periportal hepatocytes or in the mid-zonal. Anti-Glutamine Synthetase is useful in some hepatocellular carcinomas and many high grade dysplastic nodules, and therefore may be useful in recognizing these cases. A panel of antibodies against HSP70 (heat shock protein 70), GPC3, and glutamine synthetase is useful for differentiating dysplastic from early malignant hepatocellular nodules in cirrhosis. GS staining of hepatocellular lesions is useful for the differential diagnosis of focal nodular hyperplasia (FNH), hepatic adenoma (HCA), dysplastic nodules, and low grade hepatocellular carcinoma. FNH produces a “map-like” pattern when stained with Anti-Glutamine Synthetase. Conversely, HCA can stain negatively, produce border staining, or stain around the tumour veins.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC586
Antibody Isotype:
IgG2a
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Hepatocellular Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Glutamine Synthetase (GS-6 or GS) catalyzes the conversion of glutamate and ammonia to glutamine in the liver, and is expressed in pericentral hepatocytes, but not in periportal hepatocytes or in the mid-zonal. Anti-Glutamine Synthetase is useful in some hepatocellular carcinomas and many high grade dysplastic nodules, and therefore may be useful in recognizing these cases. A panel of antibodies against HSP70 (heat shock protein 70), GPC3, and glutamine synthetase is useful for differentiating dysplastic from early malignant hepatocellular nodules in cirrhosis. GS staining of hepatocellular lesions is useful for the differential diagnosis of focal nodular hyperplasia (FNH), hepatic adenoma (HCA), dysplastic nodules, and low grade hepatocellular carcinoma. FNH produces a “map-like” pattern when stained with Anti-Glutamine Synthetase. Conversely, HCA can stain negatively, produce border staining, or stain around the tumour veins.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC586
Antibody Isotype:
IgG2a
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Hepatocellular Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Glutamine Synthetase (GS-6 or GS) catalyzes the conversion of glutamate and ammonia to glutamine in the liver, and is expressed in pericentral hepatocytes, but not in periportal hepatocytes or in the mid-zonal. Anti-Glutamine Synthetase is useful in some hepatocellular carcinomas and many high grade dysplastic nodules, and therefore may be useful in recognizing these cases. A panel of antibodies against HSP70 (heat shock protein 70), GPC3, and glutamine synthetase is useful for differentiating dysplastic from early malignant hepatocellular nodules in cirrhosis. GS staining of hepatocellular lesions is useful for the differential diagnosis of focal nodular hyperplasia (FNH), hepatic adenoma (HCA), dysplastic nodules, and low grade hepatocellular carcinoma. FNH produces a “map-like” pattern when stained with Anti-Glutamine Synthetase. Conversely, HCA can stain negatively, produce border staining, or stain around the tumour veins.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC586
Antibody Isotype:
IgG2a
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Hepatocellular Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Glucose transporter type I (GLUT1), also known as SCL2A1, is a glucose transporter present in the blood-brain barrier and erythrocytes. GLUT1 overexpression is associated with tumour progression or poor prognoses of bladder, breast, cervical, colon, and lung carcinomas, as well as mesothelioma. Anti-GLUT1 is useful for distinguishing malignant mesothelioma (GLUT1(+)) from reactive mesothelium (GLUT1(-)).
Glucose transporter type I (GLUT1), also known as SCL2A1, is a glucose transporter present in the blood-brain barrier and erythrocytes. GLUT1 overexpression is associated with tumour progression or poor prognoses of bladder, breast, cervical, colon, and lung carcinomas, as well as mesothelioma. Anti-GLUT1 is useful for distinguishing malignant mesothelioma (GLUT1(+)) from reactive mesothelium (GLUT1(-)).
Glucose transporter type I (GLUT1), also known as SCL2A1, is a glucose transporter present in the blood-brain barrier and erythrocytes. GLUT1 overexpression is associated with tumour progression or poor prognoses of bladder, breast, cervical, colon, and lung carcinomas, as well as mesothelioma. Anti-GLUT1 is useful for distinguishing malignant mesothelioma (GLUT1(+)) from reactive mesothelium (GLUT1(-)).
Glucose transporter type I (GLUT1), also known as SCL2A1, is a glucose transporter present in the blood-brain barrier and erythrocytes. GLUT1 overexpression is associated with tumour progression or poor prognoses of bladder, breast, cervical, colon, and lung carcinomas, as well as mesothelioma. Anti-GLUT1 is useful for distinguishing malignant mesothelioma (GLUT1(+)) from reactive mesothelium (GLUT1(-)).
Glial Fibrillary Acidic Protein (GFAP) is an intermediate filament protein that is present in astrocytes and some ependymal cells of the central nervous system. In the peripheral nervous system, GFAP is present in Schwann cells, enteric glial cells, and satellite cells. Anti-GFAP staining is useful in differentiating neoplasms of astrocyte origin from other neoplasms in the central nervous system.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Glial Fibrillary Acidic Protein (GFAP) is an intermediate filament protein that is present in astrocytes and some ependymal cells of the central nervous system. In the peripheral nervous system, GFAP is present in Schwann cells, enteric glial cells, and satellite cells. Anti-GFAP staining is useful in differentiating neoplasms of astrocyte origin from other neoplasms in the central nervous system.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC584
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Brain
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Glial Fibrillary Acidic Protein (GFAP) is an intermediate filament protein that is present in astrocytes and some ependymal cells of the central nervous system. In the peripheral nervous system, GFAP is present in Schwann cells, enteric glial cells, and satellite cells. Anti-GFAP staining is useful in differentiating neoplasms of astrocyte origin from other neoplasms in the central nervous system.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC584
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Brain
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Glial Fibrillary Acidic Protein (GFAP) is an intermediate filament protein that is present in astrocytes and some ependymal cells of the central nervous system. In the peripheral nervous system, GFAP is present in Schwann cells, enteric glial cells, and satellite cells. Anti-GFAP staining is useful in differentiating neoplasms of astrocyte origin from other neoplasms in the central nervous system.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC584
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Brain
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
GATA3 is a transcription factor important in cell proliferation, development, and differentiation. GATA3 is mostly observed in breast and urothelial carcinomas, and is rarely present in other cancers such as endometrial endometrioid adenocarcinoma. Among the breast carcinomas, GATA3 has a lower expression in luminal B subtype breast carcinoma. Studies have found GATA3 expression to be associated with ER (estrogen receptor), PR (progesterone receptor), and HER2 in breast cancer cases. Urothelial carcinomas stain positively for GATA3 in invasive or high grade tumours, therefore Anti-GATA3 is useful for carcinoma diagnosis when those of the breast and bladder are plausible.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
GATA3 is a transcription factor important in cell proliferation, development, and differentiation. GATA3 is mostly observed in breast and urothelial carcinomas, and is rarely present in other cancers such as endometrial endometrioid adenocarcinoma. Among the breast carcinomas, GATA3 has a lower expression in luminal B subtype breast carcinoma. Studies have found GATA3 expression to be associated with ER (estrogen receptor), PR (progesterone receptor), and HER2 in breast cancer cases. Urothelial carcinomas stain positively for GATA3 in invasive or high grade tumours, therefore Anti-GATA3 is useful for carcinoma diagnosis when those of the breast and bladder are plausible.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC583
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Breast Carcinoma, Urothelial Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
GATA3 is a transcription factor important in cell proliferation, development, and differentiation. GATA3 is mostly observed in breast and urothelial carcinomas, and is rarely present in other cancers such as endometrial endometrioid adenocarcinoma. Among the breast carcinomas, GATA3 has a lower expression in luminal B subtype breast carcinoma. Studies have found GATA3 expression to be associated with ER (estrogen receptor), PR (progesterone receptor), and HER2 in breast cancer cases. Urothelial carcinomas stain positively for GATA3 in invasive or high grade tumours, therefore Anti-GATA3 is useful for carcinoma diagnosis when those of the breast and bladder are plausible.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC583
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Breast Carcinoma, Urothelial Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
GATA3 is a transcription factor important in cell proliferation, development, and differentiation. GATA3 is mostly observed in breast and urothelial carcinomas, and is rarely present in other cancers such as endometrial endometrioid adenocarcinoma. Among the breast carcinomas, GATA3 has a lower expression in luminal B subtype breast carcinoma. Studies have found GATA3 expression to be associated with ER (estrogen receptor), PR (progesterone receptor), and HER2 in breast cancer cases. Urothelial carcinomas stain positively for GATA3 in invasive or high grade tumours, therefore Anti-GATA3 is useful for carcinoma diagnosis when those of the breast and bladder are plausible.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC583
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Breast Carcinoma, Urothelial Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Galectin-3 is a lectin involved in cell adhesion, macrophage activation, angiogenesis, metastasis, and apoptosis. Anti-Galectin-3 is useful for distinguishing between benign and malignant thyroid neoplasms. Galectin-3 is also useful for recognizing anaplastic large cell lymphoma.
Galectin-3 is a lectin involved in cell adhesion, macrophage activation, angiogenesis, metastasis, and apoptosis. Anti-Galectin-3 is useful for distinguishing between benign and malignant thyroid neoplasms. Galectin-3 is also useful for recognizing anaplastic large cell lymphoma.
Galectin-3 is a lectin involved in cell adhesion, macrophage activation, angiogenesis, metastasis, and apoptosis. Anti-Galectin-3 is useful for distinguishing between benign and malignant thyroid neoplasms. Galectin-3 is also useful for recognizing anaplastic large cell lymphoma.
Galectin-3 is a lectin involved in cell adhesion, macrophage activation, angiogenesis, metastasis, and apoptosis. Anti-Galectin-3 is useful for distinguishing between benign and malignant thyroid neoplasms. Galectin-3 is also useful for recognizing anaplastic large cell lymphoma.
Follicle-Stimulating Hormone (FSH) allows for progression of ovarian folliculogenesis, and enables Sertoli cell proliferation in the testis. Anti-FSH reacts with FSH-producing cells, and therefore FSH staining is useful for classifying pituitary cancers and understanding pituitary disease.
Follicle-Stimulating Hormone (FSH) allows for progression of ovarian folliculogenesis, and enables Sertoli cell proliferation in the testis. Anti-FSH reacts with FSH-producing cells, and therefore FSH staining is useful for classifying pituitary cancers and understanding pituitary disease.
Follicle-Stimulating Hormone (FSH) allows for progression of ovarian folliculogenesis, and enables Sertoli cell proliferation in the testis. Anti-FSH reacts with FSH-producing cells, and therefore FSH staining is useful for classifying pituitary cancers and understanding pituitary disease.
Follicle-Stimulating Hormone (FSH) allows for progression of ovarian folliculogenesis, and enables Sertoli cell proliferation in the testis. Anti-FSH reacts with FSH-producing cells, and therefore FSH staining is useful for classifying pituitary cancers and understanding pituitary disease.
FOXP3 is a forkhead transcription factor family member which plays a key role in CD4+CD25+ regulatory T cell function and represents a specific marker for these cells. Specifically in IHC, FOXP3 is a marker for adult T-cell leukemia/lymphoma (ATLL). In normal lymphoid tissues, a T-cell subset in interfollicular areas shows nuclear staining. There are many characteristics of FOXP3s role in cancer, which involves tumour progression through the suppression of T-cell activity and oncogene suppression through suppressing the expression of HER2, Skp2, SATB1 and MYC oncogenes.
FOXP3 is a forkhead transcription factor family member which plays a key role in CD4+CD25+ regulatory T cell function and represents a specific marker for these cells. Specifically in IHC, FOXP3 is a marker for adult T-cell leukemia/lymphoma (ATLL). In normal lymphoid tissues, a T-cell subset in interfollicular areas shows nuclear staining. There are many characteristics of FOXP3s role in cancer, which involves tumour progression through the suppression of T-cell activity and oncogene suppression through suppressing the expression of HER2, Skp2, SATB1 and MYC oncogenes.
The GeneNav HPV Complete qPCR Kit utilizes quantitative PCR (qPCR) technology to detect all 14 High Risk human papilloma virus (HPV) subtypes, allowing physicians to identify those at risk for cervical cancer. In addition, HPV Complete enables detection of HPV types 6 and 11 which are considered low risk for cervical cancer, however they are the cause of 90% of all cases of genital warts as well as respiratory papillomatosis. This in vitro diagnostic kit allows for simultaneous detection of HPV 16 or HPV 18, nonspecific pooled detection of the other 12 high risk HPV subtypes (HPV 31, HPV 33, HPV 35, HPV 39, HPV 45, HPV 51, HPV 52, HPV 56, HPV 58, HPV 59, HPV 66, and HPV 68), and simultaneous detection of low-risk subtypes HPV 6 or 11. A human ?-Actin internal control is also used in the GeneNav HPV Complete qPCR Kit to assess specimen quality and ensure the reliability of the HPV detection results.
Product Type:
Fluorescent Probe-based qPCR
Format:
48 Test Kit
Storage Temp:
-25°C to -15°C in a non-frost-free freezer
Applications:
qPCR
Application Details:
Simultaneous detection of HPV 16 or HPV 18, nonspecific pooled detection of the other 12 high risk HPV subtypes (HPV 31, HPV 33, HPV 35, HPV 39, HPV 45, HPV 51, HPV 52, HPV 56, HPV 58, HPV 59, HPV 66, and HPV 68), and simultaneous detection of low-risk subtypes HPV 6 or 11.
The GeneNav HPV Genotyping qPCR Kit is designed for continuous monitoring of individuals who have been confirmed to be HPV positive with one of the 14 High Risk human papilloma virus (HPV) subtypes. This kit allows physicians to track patients who are at a greater risk of developing cervical cancer by identifying individuals who show persistent infection with the same HPV subtype. This in vitro diagnostic kit allows for the specific detection and discrimination of all 14 High Risk HPV subtypes: HPV 16, HPV 18, HPV 31, HPV 33, HPV 35, HPV 39, HPV 45, HPV 51, HPV 52, HPV 56, HPV 58, HPV 59, HPV 66, and HPV 68. A ?-Actin internal control is also used in the GeneNav HPV Genotyping qPCR Kit to assess specimen quality and ensure the reliability of the HPV detection results.
Product Type:
Fluorescent Probe-based qPCR
Format:
24 Test Kit
Storage Temp:
-25°C to -15°C in a non-frost-free freezer
Applications:
qPCR
Application Details:
Specific detection and discrimination between all 14 High Risk HPV Subtypes, including: HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.
The GeneNav HPV One qPCR Kit is designed for quick initial screening of individuals for the presence of all 14 High Risk human papilloma virus (HPV) subtypes allowing physicians to identify those at risk for cervical cancer. This in vitro diagnostic kit allows for the specific detection and discrimination between HPV 16, HPV 18, and nonspecific pooled detection of the other 12 high risk HPV subtypes (HPV 31, HPV 33, HPV 35, HPV 39, HPV 45, HPV 51, HPV 52, HPV 56, HPV 58, HPV 59, HPV 66, and HPV 68). A human ?-Actin internal control is also used in the GeneNav HPV One qPCR Kit to assess specimen quality and ensure the reliability of the HPV detection results.
Product Type:
Fluorescent Probe-based qPCR
Format:
48 Test Kit
Storage Temp:
-25°C to -15°C in a non-frost-free freezer
Applications:
qPCR
Application Details:
Specific detection and discrimination between HPV 16, 18, and non-specific pooled detection of HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68.
Wilms' Tumour Protein (WT1) is a transcription factor involved in the development of the urogenital system. Anti-WT1 is utilized in the differential diagnosis of pulmonary malignancies (nuclei staining) and small round cell tumours. Ewing's sarcomas, primitive neuroectodermal tumours, neuroblastomas, rhabdomyosarcomas, and rhabdoid tumours do not stain with Anti-WT1, but cytoplasmic staining may be observed. Although lung adenocarcinomas do not exhibit nuclear staining with Anti-WT1, the antibody may stain the cytoplasm. Anti-WT1 also stains serous ovarian carcinomas, but does not stain mucinous carcinomas of the ovary and pancreatobiliary carcinomas.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Wilms' Tumour Protein (WT1) is a transcription factor involved in the development of the urogenital system. Anti-WT1 is utilized in the differential diagnosis of pulmonary malignancies (nuclei staining) and small round cell tumours. Ewing's sarcomas, primitive neuroectodermal tumours, neuroblastomas, rhabdomyosarcomas, and rhabdoid tumours do not stain with Anti-WT1, but cytoplasmic staining may be observed. Although lung adenocarcinomas do not exhibit nuclear staining with Anti-WT1, the antibody may stain the cytoplasm. Anti-WT1 also stains serous ovarian carcinomas, but does not stain mucinous carcinomas of the ovary and pancreatobiliary carcinomas.
Wilms' Tumour Protein (WT1) is a transcription factor involved in the development of the urogenital system. Anti-WT1 is utilized in the differential diagnosis of pulmonary malignancies (nuclei staining) and small round cell tumours. Ewing's sarcomas, primitive neuroectodermal tumours, neuroblastomas, rhabdomyosarcomas, and rhabdoid tumours do not stain with Anti-WT1, but cytoplasmic staining may be observed. Although lung adenocarcinomas do not exhibit nuclear staining with Anti-WT1, the antibody may stain the cytoplasm. Anti-WT1 also stains serous ovarian carcinomas, but does not stain mucinous carcinomas of the ovary and pancreatobiliary carcinomas.
Wilms' Tumour Protein (WT1) is a transcription factor involved in the development of the urogenital system. Anti-WT1 is utilized in the differential diagnosis of pulmonary malignancies (nuclei staining) and small round cell tumours. Ewing's sarcomas, primitive neuroectodermal tumours, neuroblastomas, rhabdomyosarcomas, and rhabdoid tumours do not stain with Anti-WT1, but cytoplasmic staining may be observed. Although lung adenocarcinomas do not exhibit nuclear staining with Anti-WT1, the antibody may stain the cytoplasm. Anti-WT1 also stains serous ovarian carcinomas, but does not stain mucinous carcinomas of the ovary and pancreatobiliary carcinomas.
Vimentin is a component of intermediate filament in mesenchymal cells, such as endothelial cells, fibroblasts, lymphocytes, and melanocytes. Anti-Vimentin is useful for assessing whether tissue samples have been processed and preserved properly. A panel of Anti-Vimentin and Anti-Keratin is useful for differentiating melanomas from large cell lymphomas and undifferentiated carcinomas. This diagnostic grade Vimentin IVD antibody stains melanomas and schwannomas, as well as endometrial endometrioid adenocarcinomas.
Vimentin is a component of intermediate filament in mesenchymal cells, such as endothelial cells, fibroblasts, lymphocytes, and melanocytes. Anti-Vimentin is useful for assessing whether tissue samples have been processed and preserved properly. A panel of Anti-Vimentin and Anti-Keratin is useful for differentiating melanomas from large cell lymphomas and undifferentiated carcinomas. This diagnostic grade Vimentin IVD antibody stains melanomas and schwannomas, as well as endometrial endometrioid adenocarcinomas.
Vimentin is a component of intermediate filament in mesenchymal cells, such as endothelial cells, fibroblasts, lymphocytes, and melanocytes. Anti-Vimentin is useful for assessing whether tissue samples have been processed and preserved properly. A panel of Anti-Vimentin and Anti-Keratin is useful for differentiating melanomas from large cell lymphomas and undifferentiated carcinomas. This diagnostic grade Vimentin IVD antibody stains melanomas and schwannomas, as well as endometrial endometrioid adenocarcinomas.
Vimentin is a component of intermediate filament in mesenchymal cells, such as endothelial cells, fibroblasts, lymphocytes, and melanocytes. Anti-Vimentin is useful for assessing whether tissue samples have been processed and preserved properly. A panel of Anti-Vimentin and Anti-Keratin is useful for differentiating melanomas from large cell lymphomas and undifferentiated carcinomas. This diagnostic grade Vimentin IVD antibody stains melanomas and schwannomas, as well as endometrial endometrioid adenocarcinomas.
Villin is a tissue-specific actin-binding glycoprotein that is associated with the maintenance of the microvilli brush border found in the gastrointestinal mucosal epithelium. Villin is expressed in carcinomas of the gastrointestinal tract, renal cell carcinomas, pacreatic carcinomas, endometrial carcinomas, as well as carcinomas of the ovary and lungs. Anti-Villin antibodies can be useful for identifying and differentiating adenocarcinomas of these organs from other organs in the body. Additionally, it may be helpful in separating carcinoid tumors from other endocrine tumors.
Villin is a tissue-specific actin-binding glycoprotein that is associated with the maintenance of the microvilli brush border found in the gastrointestinal mucosal epithelium. Villin is expressed in carcinomas of the gastrointestinal tract, renal cell carcinomas, pacreatic carcinomas, endometrial carcinomas, as well as carcinomas of the ovary and lungs. Anti-Villin antibodies can be useful for identifying and differentiating adenocarcinomas of these organs from other organs in the body. Additionally, it may be helpful in separating carcinoid tumors from other endocrine tumors.
Villin is a tissue-specific actin-binding glycoprotein that is associated with the maintenance of the microvilli brush border found in the gastrointestinal mucosal epithelium. Villin is expressed in carcinomas of the gastrointestinal tract, renal cell carcinomas, pacreatic carcinomas, endometrial carcinomas, as well as carcinomas of the ovary and lungs. Anti-Villin antibodies can be useful for identifying and differentiating adenocarcinomas of these organs from other organs in the body. Additionally, it may be helpful in separating carcinoid tumors from other endocrine tumors.
Villin is a tissue-specific actin-binding glycoprotein that is associated with the maintenance of the microvilli brush border found in the gastrointestinal mucosal epithelium. Villin is expressed in carcinomas of the gastrointestinal tract, renal cell carcinomas, pacreatic carcinomas, endometrial carcinomas, as well as carcinomas of the ovary and lungs. Anti-Villin antibodies can be useful for identifying and differentiating adenocarcinomas of these organs from other organs in the body. Additionally, it may be helpful in separating carcinoid tumors from other endocrine tumors.
Vascular Endothelial Growth Factor (VEGF) promotes vasculogenesis and angiogenesis, and mainly affects the vascular endothelium. VEGF is associated with poor prognoses of breast carcinomas, and has been shown to be elevated in rheumatoid arthritis.
Vascular Endothelial Growth Factor (VEGF) promotes vasculogenesis and angiogenesis, and mainly affects the vascular endothelium. VEGF is associated with poor prognoses of breast carcinomas, and has been shown to be elevated in rheumatoid arthritis.
Vascular Endothelial Growth Factor (VEGF) promotes vasculogenesis and angiogenesis, and mainly affects the vascular endothelium. VEGF is associated with poor prognoses of breast carcinomas, and has been shown to be elevated in rheumatoid arthritis.
Vascular Endothelial Growth Factor (VEGF) promotes vasculogenesis and angiogenesis, and mainly affects the vascular endothelium. VEGF is associated with poor prognoses of breast carcinomas, and has been shown to be elevated in rheumatoid arthritis.
Thyroid Transcription Factor 1 (TTF-1) is present in diencephalon, lung, and thyroid. Anti-TTF-1 stains thyroid and thyroid-derived tumours, and is therefore used for distinguishing lung adenocarcinoma from germ cell tumours, malignant mesothelioma, and metastatic carcinomas from organs other than the thyroid. It is also useful for distinguishing small cell lung carcinoma from lymphoid infiltrates, and pulmonary from non-pulmonary adenocarcinomas in malignant effusions. The ability to distinguish between pulmonary and non-pulmonary adenocarcinomas is particularly useful in identifying tumours that have metastasized to the brain.
Thyroid Transcription Factor 1 (TTF-1) is present in diencephalon, lung, and thyroid. Anti-TTF-1 stains thyroid and thyroid-derived tumours, and is therefore used for distinguishing lung adenocarcinoma from germ cell tumours, malignant mesothelioma, and metastatic carcinomas from organs other than the thyroid. It is also useful for distinguishing small cell lung carcinoma from lymphoid infiltrates, and pulmonary from non-pulmonary adenocarcinomas in malignant effusions. The ability to distinguish between pulmonary and non-pulmonary adenocarcinomas is particularly useful in identifying tumours that have metastasized to the brain.
Thyroid Transcription Factor 1 (TTF-1) is present in diencephalon, lung, and thyroid. Anti-TTF-1 stains thyroid and thyroid-derived tumours, and is therefore used for distinguishing lung adenocarcinoma from germ cell tumours, malignant mesothelioma, and metastatic carcinomas from organs other than the thyroid. It is also useful for distinguishing small cell lung carcinoma from lymphoid infiltrates, and pulmonary from non-pulmonary adenocarcinomas in malignant effusions. The ability to distinguish between pulmonary and non-pulmonary adenocarcinomas is particularly useful in identifying tumours that have metastasized to the brain.
Thyroid Transcription Factor 1 (TTF-1) is present in diencephalon, lung, and thyroid. Anti-TTF-1 stains thyroid and thyroid-derived tumours, and is therefore used for distinguishing lung adenocarcinoma from germ cell tumours, malignant mesothelioma, and metastatic carcinomas from organs other than the thyroid. It is also useful for distinguishing small cell lung carcinoma from lymphoid infiltrates, and pulmonary from non-pulmonary adenocarcinomas in malignant effusions. The ability to distinguish between pulmonary and non-pulmonary adenocarcinomas is particularly useful in identifying tumours that have metastasized to the brain.
Thyroid-Stimulating Hormone (TSH) is secreted by thyrotrope cells in the anterior pituitary gland. Anti-TSH stains thyrotrophs and is useful for categorizing pituitary tumours, as well as for recognizing primary and metastatic pituitary gland tumours.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Thyroid-Stimulating Hormone (TSH) is secreted by thyrotrope cells in the anterior pituitary gland. Anti-TSH stains thyrotrophs and is useful for categorizing pituitary tumours, as well as for recognizing primary and metastatic pituitary gland tumours.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC679
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Pituitary
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Thyroid-Stimulating Hormone (TSH) is secreted by thyrotrope cells in the anterior pituitary gland. Anti-TSH stains thyrotrophs and is useful for categorizing pituitary tumours, as well as for recognizing primary and metastatic pituitary gland tumours.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC679
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Pituitary
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Thyroid-Stimulating Hormone (TSH) is secreted by thyrotrope cells in the anterior pituitary gland. Anti-TSH stains thyrotrophs and is useful for categorizing pituitary tumours, as well as for recognizing primary and metastatic pituitary gland tumours.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC679
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Pituitary
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Topoisomerase II alpha (TOP2A) is a member of a highly conserved group of enzymes that plays important roles in synthesis and transcription of DNA as well as chromosomal segregation during mitosis. The overexpression of TOP2A has been correlated with increased risk of progression in various cancers, and it has been a target for the development of anti-polymerase inhibitors to treat cancer.
Topoisomerase II alpha (TOP2A) is a member of a highly conserved group of enzymes that plays important roles in synthesis and transcription of DNA as well as chromosomal segregation during mitosis. The overexpression of TOP2A has been correlated with increased risk of progression in various cancers, and it has been a target for the development of anti-polymerase inhibitors to treat cancer.
Topoisomerase II alpha (TOP2A) is a member of a highly conserved group of enzymes that plays important roles in synthesis and transcription of DNA as well as chromosomal segregation during mitosis. The overexpression of TOP2A has been correlated with increased risk of progression in various cancers, and it has been a target for the development of anti-polymerase inhibitors to treat cancer.
FOXP3 is a forkhead transcription factor family member which plays a key role in CD4+CD25+ regulatory T cell function and represents a specific marker for these cells. Specifically in IHC, FOXP3 is a marker for adult T-cell leukemia/lymphoma (ATLL). In normal lymphoid tissues, a T-cell subset in interfollicular areas shows nuclear staining. There are many characteristics of FOXP3s role in cancer, which involves tumour progression through the suppression of T-cell activity and oncogene suppression through suppressing the expression of HER2, Skp2, SATB1 and MYC oncogenes.
FOXP3 is a forkhead transcription factor family member which plays a key role in CD4+CD25+ regulatory T cell function and represents a specific marker for these cells. Specifically in IHC, FOXP3 is a marker for adult T-cell leukemia/lymphoma (ATLL). In normal lymphoid tissues, a T-cell subset in interfollicular areas shows nuclear staining. There are many characteristics of FOXP3s role in cancer, which involves tumour progression through the suppression of T-cell activity and oncogene suppression through suppressing the expression of HER2, Skp2, SATB1 and MYC oncogenes.
Flt-1, also known as Fms Related Tyrosine Kinase 1 or VEGFR1 (Vascular Endothelial Growth Factor Receptor 1), is a tyrosine kinase involved in lymphangiogenesis, angiogenesis, and wound healing. It is present in endothelial cells, osteoblasts, placental trophoblasts, renal mesangial cells, and some hematopoietic stem cells. Anti-Flt-1/VEGFR1 is useful for identifying carcinomas of the larynx and esophagus.
Flt-1, also known as Fms Related Tyrosine Kinase 1 or VEGFR1 (Vascular Endothelial Growth Factor Receptor 1), is a tyrosine kinase involved in lymphangiogenesis, angiogenesis, and wound healing. It is present in endothelial cells, osteoblasts, placental trophoblasts, renal mesangial cells, and some hematopoietic stem cells. Anti-Flt-1/VEGFR1 is useful for identifying carcinomas of the larynx and esophagus.
Flt-1, also known as Fms Related Tyrosine Kinase 1 or VEGFR1 (Vascular Endothelial Growth Factor Receptor 1), is a tyrosine kinase involved in lymphangiogenesis, angiogenesis, and wound healing. It is present in endothelial cells, osteoblasts, placental trophoblasts, renal mesangial cells, and some hematopoietic stem cells. Anti-Flt-1/VEGFR1 is useful for identifying carcinomas of the larynx and esophagus.
Flt-1, also known as Fms Related Tyrosine Kinase 1 or VEGFR1 (Vascular Endothelial Growth Factor Receptor 1), is a tyrosine kinase involved in lymphangiogenesis, angiogenesis, and wound healing. It is present in endothelial cells, osteoblasts, placental trophoblasts, renal mesangial cells, and some hematopoietic stem cells. Anti-Flt-1/VEGFR1 is useful for identifying carcinomas of the larynx and esophagus.
Fibronectin is a glycoprotein that contributes to cell adhesion, migration, and metastasis. Renal cancer cells exhibit higher expression of fibronectin, therefore Anti-Fibronectin is useful for assessing the progression and aggressiveness of renal cancer cells.
Fibronectin is a glycoprotein that contributes to cell adhesion, migration, and metastasis. Renal cancer cells exhibit higher expression of fibronectin, therefore Anti-Fibronectin is useful for assessing the progression and aggressiveness of renal cancer cells.
Fibronectin is a glycoprotein that contributes to cell adhesion, migration, and metastasis. Renal cancer cells exhibit higher expression of fibronectin, therefore Anti-Fibronectin is useful for assessing the progression and aggressiveness of renal cancer cells.
Fibronectin is a glycoprotein that contributes to cell adhesion, migration, and metastasis. Renal cancer cells exhibit higher expression of fibronectin, therefore Anti-Fibronectin is useful for assessing the progression and aggressiveness of renal cancer cells.
Enhancer of Zeste Homolog 2 (EZH2) is a methylase of histone H3 that silences gene expression in those regions. EZH2 is overexpressed or mutated in gastric, prostate, uterine, breast, and renal cell cancers, as well as in melanoma and most B- and T-cell lymphomas. Although EZH2 is usually present in follicular centers, it is not expressed in the mantle zones, plasma cells, follicular or interfollicular T-lymphocytes, natural killer T-lymphocytes, plasmacytoma, lymphoplasmacytic lymphoma, or MALT lymphoma. EZH2 is rarely present in normal breast duct epithelium and in normal and hyperplastic lymph node. Anti-EZH2 is also useful for detecting lymphoma and non-small cell lung cancers. EZH2 is associated with tumour proliferation and can be used in staining panels to distinguish aggressive lymphomas from less aggressive lymphomas or normal cells.
Enhancer of Zeste Homolog 2 (EZH2) is a methylase of histone H3 that silences gene expression in those regions. EZH2 is overexpressed or mutated in gastric, prostate, uterine, breast, and renal cell cancers, as well as in melanoma and most B- and T-cell lymphomas. Although EZH2 is usually present in follicular centers, it is not expressed in the mantle zones, plasma cells, follicular or interfollicular T-lymphocytes, natural killer T-lymphocytes, plasmacytoma, lymphoplasmacytic lymphoma, or MALT lymphoma. EZH2 is rarely present in normal breast duct epithelium and in normal and hyperplastic lymph node. Anti-EZH2 is also useful for detecting lymphoma and non-small cell lung cancers. EZH2 is associated with tumour proliferation and can be used in staining panels to distinguish aggressive lymphomas from less aggressive lymphomas or normal cells.
Enhancer of Zeste Homolog 2 (EZH2) is a methylase of histone H3 that silences gene expression in those regions. EZH2 is overexpressed or mutated in gastric, prostate, uterine, breast, and renal cell cancers, as well as in melanoma and most B- and T-cell lymphomas. Although EZH2 is usually present in follicular centers, it is not expressed in the mantle zones, plasma cells, follicular or interfollicular T-lymphocytes, natural killer T-lymphocytes, plasmacytoma, lymphoplasmacytic lymphoma, or MALT lymphoma. EZH2 is rarely present in normal breast duct epithelium and in normal and hyperplastic lymph node. Anti-EZH2 is also useful for detecting lymphoma and non-small cell lung cancers. EZH2 is associated with tumour proliferation and can be used in staining panels to distinguish aggressive lymphomas from less aggressive lymphomas or normal cells.
Enhancer of Zeste Homolog 2 (EZH2) is a methylase of histone H3 that silences gene expression in those regions. EZH2 is overexpressed or mutated in gastric, prostate, uterine, breast, and renal cell cancers, as well as in melanoma and most B- and T-cell lymphomas. Although EZH2 is usually present in follicular centers, it is not expressed in the mantle zones, plasma cells, follicular or interfollicular T-lymphocytes, natural killer T-lymphocytes, plasmacytoma, lymphoplasmacytic lymphoma, or MALT lymphoma. EZH2 is rarely present in normal breast duct epithelium and in normal and hyperplastic lymph node. Anti-EZH2 is also useful for detecting lymphoma and non-small cell lung cancers. EZH2 is associated with tumour proliferation and can be used in staining panels to distinguish aggressive lymphomas from less aggressive lymphomas or normal cells.
Enhancer of Zeste Homolog 2 (EZH2) is a methylase of histone H3 that silences gene expression in those regions. EZH2 is overexpressed or mutated in gastric, prostate, uterine, breast, and renal cell cancers, as well as in melanoma and most B- and T-cell lymphomas. Although EZH2 is usually present in follicular centers, it is not expressed in the mantle zones, plasma cells, follicular or interfollicular T-lymphocytes, natural killer T-lymphocytes, plasmacytoma, lymphoplasmacytic lymphoma, or MALT lymphoma. EZH2 is rarely present in normal breast duct epithelium and in normal and hyperplastic lymph node. Anti-EZH2 is also useful for detecting lymphoma and non-small cell lung cancers. EZH2 is associated with tumour proliferation and can be used in staining panels to distinguish aggressive lymphomas from less aggressive lymphomas or normal cells.
Enhancer of Zeste Homolog 2 (EZH2) is a methylase of histone H3 that silences gene expression in those regions. EZH2 is overexpressed or mutated in gastric, prostate, uterine, breast, and renal cell cancers, as well as in melanoma and most B- and T-cell lymphomas. Although EZH2 is usually present in follicular centers, it is not expressed in the mantle zones, plasma cells, follicular or interfollicular T-lymphocytes, natural killer T-lymphocytes, plasmacytoma, lymphoplasmacytic lymphoma, or MALT lymphoma. EZH2 is rarely present in normal breast duct epithelium and in normal and hyperplastic lymph node. Anti-EZH2 is also useful for detecting lymphoma and non-small cell lung cancers. EZH2 is associated with tumour proliferation and can be used in staining panels to distinguish aggressive lymphomas from less aggressive lymphomas or normal cells.
Enhancer of Zeste Homolog 2 (EZH2) is a methylase of histone H3 that silences gene expression in those regions. EZH2 is overexpressed or mutated in gastric, prostate, uterine, breast, and renal cell cancers, as well as in melanoma and most B- and T-cell lymphomas. Although EZH2 is usually present in follicular centers, it is not expressed in the mantle zones, plasma cells, follicular or interfollicular T-lymphocytes, natural killer T-lymphocytes, plasmacytoma, lymphoplasmacytic lymphoma, or MALT lymphoma. EZH2 is rarely present in normal breast duct epithelium and in normal and hyperplastic lymph node. Anti-EZH2 is also useful for detecting lymphoma and non-small cell lung cancers. EZH2 is associated with tumour proliferation and can be used in staining panels to distinguish aggressive lymphomas from less aggressive lymphomas or normal cells.
Enhancer of Zeste Homolog 2 (EZH2) is a methylase of histone H3 that silences gene expression in those regions. EZH2 is overexpressed or mutated in gastric, prostate, uterine, breast, and renal cell cancers, as well as in melanoma and most B- and T-cell lymphomas. Although EZH2 is usually present in follicular centers, it is not expressed in the mantle zones, plasma cells, follicular or interfollicular T-lymphocytes, natural killer T-lymphocytes, plasmacytoma, lymphoplasmacytic lymphoma, or MALT lymphoma. EZH2 is rarely present in normal breast duct epithelium and in normal and hyperplastic lymph node. Anti-EZH2 is also useful for detecting lymphoma and non-small cell lung cancers. EZH2 is associated with tumour proliferation and can be used in staining panels to distinguish aggressive lymphomas from less aggressive lymphomas or normal cells.
Estrogen Receptors (ER) are a group of nuclear hormone receptors activated by the hormone estrogen. ER is found in normal epithelial cells of the breast and endometrium, as well as in breast cancer cells.
Estrogen Receptors (ER) are a group of nuclear hormone receptors activated by the hormone estrogen. ER is found in normal epithelial cells of the breast and endometrium, as well as in breast cancer cells.
Estrogen Receptors (ER) are a group of nuclear hormone receptors activated by the hormone estrogen. ER is found in normal epithelial cells of the breast and endometrium, as well as in breast cancer cells.
Estrogen Receptors (ER) are a group of nuclear hormone receptors activated by the hormone estrogen. ER is found in normal epithelial cells of the breast and endometrium, as well as in breast cancer cells.
Estrogen Receptors (ER) are a group of nuclear hormone receptors activated by the hormone estrogen. ER is found in normal epithelial cells of the breast and endometrium, as well as in breast cancer cells.
Estrogen Receptors (ER) are a group of nuclear hormone receptors activated by the hormone estrogen. ER is found in normal epithelial cells of the breast and endometrium, as well as in breast cancer cells.
Estrogen Receptors (ER) are a group of nuclear hormone receptors activated by the hormone estrogen. ER is found in normal epithelial cells of the breast and endometrium, as well as in breast cancer cells.
Estrogen Receptors (ER) are a group of nuclear hormone receptors activated by the hormone estrogen. ER is found in normal epithelial cells of the breast and endometrium, as well as in breast cancer cells.
Erythroblastosis Virus E26 Transforming Sequence Related Gene (ERG) facilitates endothelial homeostasis. ERG is found in malignant and benign vascular endothelial tumours, including hemangiomas and Kaposi's sarcoma. ERG is present in various prostate carcinomas, but is absent in breast, colon, and urothelium carcinomas. Anti-ERG is useful for differentiating prostate carcinoma from non-prostatic epithelial tumours, and for recognizing vascular endothelial neoplasms.
Erythroblastosis Virus E26 Transforming Sequence Related Gene (ERG) facilitates endothelial homeostasis. ERG is found in malignant and benign vascular endothelial tumours, including hemangiomas and Kaposi's sarcoma. ERG is present in various prostate carcinomas, but is absent in breast, colon, and urothelium carcinomas. Anti-ERG is useful for differentiating prostate carcinoma from non-prostatic epithelial tumours, and for recognizing vascular endothelial neoplasms.
Erythroblastosis Virus E26 Transforming Sequence Related Gene (ERG) facilitates endothelial homeostasis. ERG is found in malignant and benign vascular endothelial tumours, including hemangiomas and Kaposi's sarcoma. ERG is present in various prostate carcinomas, but is absent in breast, colon, and urothelium carcinomas. Anti-ERG is useful for differentiating prostate carcinoma from non-prostatic epithelial tumours, and for recognizing vascular endothelial neoplasms.
Erythroblastosis Virus E26 Transforming Sequence Related Gene (ERG) facilitates endothelial homeostasis. ERG is found in malignant and benign vascular endothelial tumours, including hemangiomas and Kaposi's sarcoma. ERG is present in various prostate carcinomas, but is absent in breast, colon, and urothelium carcinomas. Anti-ERG is useful for differentiating prostate carcinoma from non-prostatic epithelial tumours, and for recognizing vascular endothelial neoplasms.
Excision Repair Cross Complementing 1 (ERCC1) is a DNA repair enzyme involved in the repair of UV-induced DNA damage. ERCC1 overexpression is associated with tumour progression in many malignancies, such as ovarian cancer, head squamous cell carcinoma, non-small cell lung cancer (NSCLC), and esophageal cancer.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Excision Repair Cross Complementing 1 (ERCC1) is a DNA repair enzyme involved in the repair of UV-induced DNA damage. ERCC1 overexpression is associated with tumour progression in many malignancies, such as ovarian cancer, head squamous cell carcinoma, non-small cell lung cancer (NSCLC), and esophageal cancer.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC568
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Prostate, Prostate Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Excision Repair Cross Complementing 1 (ERCC1) is a DNA repair enzyme involved in the repair of UV-induced DNA damage. ERCC1 overexpression is associated with tumour progression in many malignancies, such as ovarian cancer, head squamous cell carcinoma, non-small cell lung cancer (NSCLC), and esophageal cancer.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC568
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Prostate, Prostate Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Excision Repair Cross Complementing 1 (ERCC1) is a DNA repair enzyme involved in the repair of UV-induced DNA damage. ERCC1 overexpression is associated with tumour progression in many malignancies, such as ovarian cancer, head squamous cell carcinoma, non-small cell lung cancer (NSCLC), and esophageal cancer.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC568
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Prostate, Prostate Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Epithelial Cell Adhesion Molecule (EpCAM) is a transmembrane glycoprotein that mediates cell-cell adhesion in epithelia. It is normally present on most baso-lateral surfaces of normal epithelial cells and is absent in myoepithelial cells, hepatocytes, adult squamous epithelia, mesothelial cells, and fibroblasts. Anti-EpCAM stains most adenocarcinomas and neuroendocrine tumours, including small cell carcinomas. A minority of renal clear cell carcinoma, renal oncocytoma, and hepatocellular carcinoma stain positively for EpCAM, while Anti-EpCAM stains nearly all basal cell carcinoma. Anti-EpCAM stains chromophobe renal cell carcinoma, papillary renal cell carcinoma, and cholangiocarcinoma more frequently. Anti-EpCAM can be useful for distinguishing malignancy in the peritoneal and pleural cavities.
Epithelial Cell Adhesion Molecule (EpCAM) is a transmembrane glycoprotein that mediates cell-cell adhesion in epithelia. It is normally present on most baso-lateral surfaces of normal epithelial cells and is absent in myoepithelial cells, hepatocytes, adult squamous epithelia, mesothelial cells, and fibroblasts. Anti-EpCAM stains most adenocarcinomas and neuroendocrine tumours, including small cell carcinomas. A minority of renal clear cell carcinoma, renal oncocytoma, and hepatocellular carcinoma stain positively for EpCAM, while Anti-EpCAM stains nearly all basal cell carcinoma. Anti-EpCAM stains chromophobe renal cell carcinoma, papillary renal cell carcinoma, and cholangiocarcinoma more frequently. Anti-EpCAM can be useful for distinguishing malignancy in the peritoneal and pleural cavities.
Epithelial Cell Adhesion Molecule (EpCAM) is a transmembrane glycoprotein that mediates cell-cell adhesion in epithelia. It is normally present on most baso-lateral surfaces of normal epithelial cells and is absent in myoepithelial cells, hepatocytes, adult squamous epithelia, mesothelial cells, and fibroblasts. Anti-EpCAM stains most adenocarcinomas and neuroendocrine tumours, including small cell carcinomas. A minority of renal clear cell carcinoma, renal oncocytoma, and hepatocellular carcinoma stain positively for EpCAM, while Anti-EpCAM stains nearly all basal cell carcinoma. Anti-EpCAM stains chromophobe renal cell carcinoma, papillary renal cell carcinoma, and cholangiocarcinoma more frequently. Anti-EpCAM can be useful for distinguishing malignancy in the peritoneal and pleural cavities.
Epithelial Cell Adhesion Molecule (EpCAM) is a transmembrane glycoprotein that mediates cell-cell adhesion in epithelia. It is normally present on most baso-lateral surfaces of normal epithelial cells and is absent in myoepithelial cells, hepatocytes, adult squamous epithelia, mesothelial cells, and fibroblasts. Anti-EpCAM stains most adenocarcinomas and neuroendocrine tumours, including small cell carcinomas. A minority of renal clear cell carcinoma, renal oncocytoma, and hepatocellular carcinoma stain positively for EpCAM, while Anti-EpCAM stains nearly all basal cell carcinoma. Anti-EpCAM stains chromophobe renal cell carcinoma, papillary renal cell carcinoma, and cholangiocarcinoma more frequently. Anti-EpCAM can be useful for distinguishing malignancy in the peritoneal and pleural cavities.
Epithelial Membrane Antigen (EMA) is a mucin glycoprotein expressed on apical epithelial cells. Anti-EMA positively stains normal and neoplastic cells including sweat glands, mammary epithelia, and squamous epithelia. Adrenal carcinoma, seminomas, paraganglioma, hepatocellular carcinoma, and embryonal carcinomas exhibit a negative stain. As Anti-EMA commonly reacts positively with meningioma, it is useful for differentiating this tumour from other intracranial neoplasms such as schwannomas.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Epithelial Membrane Antigen (EMA) is a mucin glycoprotein expressed on apical epithelial cells. Anti-EMA positively stains normal and neoplastic cells including sweat glands, mammary epithelia, and squamous epithelia. Adrenal carcinoma, seminomas, paraganglioma, hepatocellular carcinoma, and embryonal carcinomas exhibit a negative stain. As Anti-EMA commonly reacts positively with meningioma, it is useful for differentiating this tumour from other intracranial neoplasms such as schwannomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC566
Antibody Isotype:
IgG2a
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Breast, Skin
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Epithelial Membrane Antigen (EMA) is a mucin glycoprotein expressed on apical epithelial cells. Anti-EMA positively stains normal and neoplastic cells including sweat glands, mammary epithelia, and squamous epithelia. Adrenal carcinoma, seminomas, paraganglioma, hepatocellular carcinoma, and embryonal carcinomas exhibit a negative stain. As Anti-EMA commonly reacts positively with meningioma, it is useful for differentiating this tumour from other intracranial neoplasms such as schwannomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC566
Antibody Isotype:
IgG2a
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Breast, Skin
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Epithelial Membrane Antigen (EMA) is a mucin glycoprotein expressed on apical epithelial cells. Anti-EMA positively stains normal and neoplastic cells including sweat glands, mammary epithelia, and squamous epithelia. Adrenal carcinoma, seminomas, paraganglioma, hepatocellular carcinoma, and embryonal carcinomas exhibit a negative stain. As Anti-EMA commonly reacts positively with meningioma, it is useful for differentiating this tumour from other intracranial neoplasms such as schwannomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC566
Antibody Isotype:
IgG2a
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Breast, Skin
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Epidermal Growth Factor Receptor (EGFR) is a tyrosine kinase present in gliocytes, epithelial cells, fibroblasts, keratinocytes, and other cell types. EGFR is overexpressed in various cancers including those of the colon, pancreas, oropharynx, stomach, and non–small cell lung, as well as head and neck squamous carcinoma and anal squamous carcinoma. EGFR expression is common in breast cancer, especially in triple-negative and basal-like breast carcinomas, and recent research has also found EGFR expressed in malignant bone and soft tissue cancers. Anti-EGFR is useful for detecting epithelioid and synovial sarcoma.
Epidermal Growth Factor Receptor (EGFR) is a tyrosine kinase present in gliocytes, epithelial cells, fibroblasts, keratinocytes, and other cell types. EGFR is overexpressed in various cancers including those of the colon, pancreas, oropharynx, stomach, and non–small cell lung, as well as head and neck squamous carcinoma and anal squamous carcinoma. EGFR expression is common in breast cancer, especially in triple-negative and basal-like breast carcinomas, and recent research has also found EGFR expressed in malignant bone and soft tissue cancers. Anti-EGFR is useful for detecting epithelioid and synovial sarcoma.
Epidermal Growth Factor Receptor (EGFR) is a tyrosine kinase present in gliocytes, epithelial cells, fibroblasts, keratinocytes, and other cell types. EGFR is overexpressed in various cancers including those of the colon, pancreas, oropharynx, stomach, and non–small cell lung, as well as head and neck squamous carcinoma and anal squamous carcinoma. EGFR expression is common in breast cancer, especially in triple-negative and basal-like breast carcinomas, and recent research has also found EGFR expressed in malignant bone and soft tissue cancers. Anti-EGFR is useful for detecting epithelioid and synovial sarcoma.
Epidermal Growth Factor Receptor (EGFR) is a tyrosine kinase present in gliocytes, epithelial cells, fibroblasts, keratinocytes, and other cell types. EGFR is overexpressed in various cancers including those of the colon, pancreas, oropharynx, stomach, and non–small cell lung, as well as head and neck squamous carcinoma and anal squamous carcinoma. EGFR expression is common in breast cancer, especially in triple-negative and basal-like breast carcinomas, and recent research has also found EGFR expressed in malignant bone and soft tissue cancers. Anti-EGFR is useful for detecting epithelioid and synovial sarcoma.
E-cadherin is an intercellular adhesion molecule present in epithelial cells. Anti-E-cadherin stains glandular epithelium, as well as lung, gastrointestinal, and ovarian adenocarcinomas. A panel of antibodies against E-cadherin and p120 is also used to differentiate ductal (membranous staining) and lobular breast cancer (cytoplasmic staining). Anti-E-cadherin also stains some thyroid cancers.
E-cadherin is an intercellular adhesion molecule present in epithelial cells. Anti-E-cadherin stains glandular epithelium, as well as lung, gastrointestinal, and ovarian adenocarcinomas. A panel of antibodies against E-cadherin and p120 is also used to differentiate ductal (membranous staining) and lobular breast cancer (cytoplasmic staining). Anti-E-cadherin also stains some thyroid cancers.
E-cadherin is an intercellular adhesion molecule present in epithelial cells. Anti-E-cadherin stains glandular epithelium, as well as lung, gastrointestinal, and ovarian adenocarcinomas. A panel of antibodies against E-cadherin and p120 is also used to differentiate ductal (membranous staining) and lobular breast cancer (cytoplasmic staining). Anti-E-cadherin also stains some thyroid cancers.
E-cadherin is an intercellular adhesion molecule present in epithelial cells. Anti-E-cadherin stains glandular epithelium, as well as lung, gastrointestinal, and ovarian adenocarcinomas. A panel of antibodies against E-cadherin and p120 is also used to differentiate ductal (membranous staining) and lobular breast cancer (cytoplasmic staining). Anti-E-cadherin also stains some thyroid cancers.
DOG1, also known as Discovered on GIST-1, is a marker that is highly specific for gastrointestinal stromal tumour (GIST). Anti-DOG1 is extremely sensitive for the detection of GIST and its diagnosis. Although some GIST stain weakly for c-kit, DOG1 is expressed in the vast majority of GIST cases. Reports have also indicated DOG1 as a marker for salivary acinar and intercalated duct differentiation.
DOG1, also known as Discovered on GIST-1, is a marker that is highly specific for gastrointestinal stromal tumour (GIST). Anti-DOG1 is extremely sensitive for the detection of GIST and its diagnosis. Although some GIST stain weakly for c-kit, DOG1 is expressed in the vast majority of GIST cases. Reports have also indicated DOG1 as a marker for salivary acinar and intercalated duct differentiation.
DOG1, also known as Discovered on GIST-1, is a marker that is highly specific for gastrointestinal stromal tumour (GIST). Anti-DOG1 is extremely sensitive for the detection of GIST and its diagnosis. Although some GIST stain weakly for c-kit, DOG1 is expressed in the vast majority of GIST cases. Reports have also indicated DOG1 as a marker for salivary acinar and intercalated duct differentiation.
DOG1, also known as Discovered on GIST-1, is a marker that is highly specific for gastrointestinal stromal tumour (GIST). Anti-DOG1 is extremely sensitive for the detection of GIST and its diagnosis. Although some GIST stain weakly for c-kit, DOG1 is expressed in the vast majority of GIST cases. Reports have also indicated DOG1 as a marker for salivary acinar and intercalated duct differentiation.
DOG1, also known as Discovered on GIST-1, is a marker that is highly specific for gastrointestinal stromal tumour (GIST). Anti-DOG1 is extremely sensitive for the detection of GIST and its diagnosis. Although some GIST stain weakly for c-kit, DOG1 is expressed in the vast majority of GIST cases. Reports have also indicated DOG1 as a marker for salivary acinar and intercalated duct differentiation.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
DOG1, also known as Discovered on GIST-1, is a marker that is highly specific for gastrointestinal stromal tumour (GIST). Anti-DOG1 is extremely sensitive for the detection of GIST and its diagnosis. Although some GIST stain weakly for c-kit, DOG1 is expressed in the vast majority of GIST cases. Reports have also indicated DOG1 as a marker for salivary acinar and intercalated duct differentiation.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC562
Antibody Isotype:
IgG1, kappa
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Gastrointestinal Stromal Tumor
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
DOG1, also known as Discovered on GIST-1, is a marker that is highly specific for gastrointestinal stromal tumour (GIST). Anti-DOG1 is extremely sensitive for the detection of GIST and its diagnosis. Although some GIST stain weakly for c-kit, DOG1 is expressed in the vast majority of GIST cases. Reports have also indicated DOG1 as a marker for salivary acinar and intercalated duct differentiation.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC562
Antibody Isotype:
IgG1, kappa
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Gastrointestinal Stromal Tumor
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
DOG1, also known as Discovered on GIST-1, is a marker that is highly specific for gastrointestinal stromal tumour (GIST). Anti-DOG1 is extremely sensitive for the detection of GIST and its diagnosis. Although some GIST stain weakly for c-kit, DOG1 is expressed in the vast majority of GIST cases. Reports have also indicated DOG1 as a marker for salivary acinar and intercalated duct differentiation.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC562
Antibody Isotype:
IgG1, kappa
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Gastrointestinal Stromal Tumor
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Desmoglein-3 Antibody (DSG3) is a component of desmosomes in vertebrate epithelial cells. It identifies pulmonary squamous cell carcinomas from other types of lung cancer with a highly specificity and sensitivity. Studies show the upregulation of DSG3 correlated with metastasis in a number of cancers including lung cancers. The expression of DSG3 indicates a poor prognosis and portends a more aggressive clinical outcome.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Desmoglein-3 Antibody (DSG3) is a component of desmosomes in vertebrate epithelial cells. It identifies pulmonary squamous cell carcinomas from other types of lung cancer with a highly specificity and sensitivity. Studies show the upregulation of DSG3 correlated with metastasis in a number of cancers including lung cancers. The expression of DSG3 indicates a poor prognosis and portends a more aggressive clinical outcome.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC083
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Skin Cancer
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Desmoglein-3 Antibody (DSG3) is a component of desmosomes in vertebrate epithelial cells. It identifies pulmonary squamous cell carcinomas from other types of lung cancer with a highly specificity and sensitivity. Studies show the upregulation of DSG3 correlated with metastasis in a number of cancers including lung cancers. The expression of DSG3 indicates a poor prognosis and portends a more aggressive clinical outcome.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC083
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Skin Cancer
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Desmoglein-3 Antibody (DSG3) is a component of desmosomes in vertebrate epithelial cells. It identifies pulmonary squamous cell carcinomas from other types of lung cancer with a highly specificity and sensitivity. Studies show the upregulation of DSG3 correlated with metastasis in a number of cancers including lung cancers. The expression of DSG3 indicates a poor prognosis and portends a more aggressive clinical outcome.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC083
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Skin Cancer
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Desmin is a type III intermediate filament present in normal smooth, skeletal, and cardiac muscle cells. Analysis by light microscopy suggests desmin localizes towards the periphery of Z-lines in striated muscle fibrils. Desmin connects cytoplasmic dense bodies to membranous dense plaques in smooth muscles. Anti-Desmin stains rhabdomyomas, leiomyosarcoma, rhabdomyosarcoma, leiomyomas, and perivascular cells from skin glomus tumours, and is used to identify the myogenic characteristics of tumours. Desmin can also be found in myofibroblasts and desmoid fibromatosis.
Desmin is a type III intermediate filament present in normal smooth, skeletal, and cardiac muscle cells. Analysis by light microscopy suggests desmin localizes towards the periphery of Z-lines in striated muscle fibrils. Desmin connects cytoplasmic dense bodies to membranous dense plaques in smooth muscles. Anti-Desmin stains rhabdomyomas, leiomyosarcoma, rhabdomyosarcoma, leiomyomas, and perivascular cells from skin glomus tumours, and is used to identify the myogenic characteristics of tumours. Desmin can also be found in myofibroblasts and desmoid fibromatosis.
Desmin is a type III intermediate filament present in normal smooth, skeletal, and cardiac muscle cells. Analysis by light microscopy suggests desmin localizes towards the periphery of Z-lines in striated muscle fibrils. Desmin connects cytoplasmic dense bodies to membranous dense plaques in smooth muscles. Anti-Desmin stains rhabdomyomas, leiomyosarcoma, rhabdomyosarcoma, leiomyomas, and perivascular cells from skin glomus tumours, and is used to identify the myogenic characteristics of tumours. Desmin can also be found in myofibroblasts and desmoid fibromatosis.
Desmin is a type III intermediate filament present in normal smooth, skeletal, and cardiac muscle cells. Analysis by light microscopy suggests desmin localizes towards the periphery of Z-lines in striated muscle fibrils. Desmin connects cytoplasmic dense bodies to membranous dense plaques in smooth muscles. Anti-Desmin stains rhabdomyomas, leiomyosarcoma, rhabdomyosarcoma, leiomyomas, and perivascular cells from skin glomus tumours, and is used to identify the myogenic characteristics of tumours. Desmin can also be found in myofibroblasts and desmoid fibromatosis.
Cytokeratin 8 & 18 are present in various epithelia including that of the breast, thyroid, respiratory tract, and gastrointestinal tract. Anti-Cytokeratin 8 & 18 stains adenocarcinomas and most non-keratinizing squamous carcinomas, but does not stain keratinizing squamous carcinomas. Since Cytokeratin 18 is scarce in normal epidermis, Anti-Cytokeratin 8 & 18 is used to detect Paget cells in such samples. Cytokeratin 8 & 18 helps identify colorectal carcinoma metastases as it is more sensitive than genetic tests.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cytokeratin 8 & 18 are present in various epithelia including that of the breast, thyroid, respiratory tract, and gastrointestinal tract. Anti-Cytokeratin 8 & 18 stains adenocarcinomas and most non-keratinizing squamous carcinomas, but does not stain keratinizing squamous carcinomas. Since Cytokeratin 18 is scarce in normal epidermis, Anti-Cytokeratin 8 & 18 is used to detect Paget cells in such samples. Cytokeratin 8 & 18 helps identify colorectal carcinoma metastases as it is more sensitive than genetic tests.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit/Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC559
Antibody Isotype:
Rabbit IgG/Mouse IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Breast Ductal Carcinoma, Colon Cancer
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cytokeratin 8 & 18 are present in various epithelia including that of the breast, thyroid, respiratory tract, and gastrointestinal tract. Anti-Cytokeratin 8 & 18 stains adenocarcinomas and most non-keratinizing squamous carcinomas, but does not stain keratinizing squamous carcinomas. Since Cytokeratin 18 is scarce in normal epidermis, Anti-Cytokeratin 8 & 18 is used to detect Paget cells in such samples. Cytokeratin 8 & 18 helps identify colorectal carcinoma metastases as it is more sensitive than genetic tests.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit/Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC559
Antibody Isotype:
Rabbit IgG/Mouse IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Breast Ductal Carcinoma, Colon Cancer
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cytokeratin 8 & 18 are present in various epithelia including that of the breast, thyroid, respiratory tract, and gastrointestinal tract. Anti-Cytokeratin 8 & 18 stains adenocarcinomas and most non-keratinizing squamous carcinomas, but does not stain keratinizing squamous carcinomas. Since Cytokeratin 18 is scarce in normal epidermis, Anti-Cytokeratin 8 & 18 is used to detect Paget cells in such samples. Cytokeratin 8 & 18 helps identify colorectal carcinoma metastases as it is more sensitive than genetic tests.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit/Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC559
Antibody Isotype:
Rabbit IgG/Mouse IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Breast Ductal Carcinoma, Colon Cancer
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cytokeratin 8 (CK8) is present in single-layer epithelial tissue. CK8 frequently interacts with Cytokeratin 18, and Anti-Cytokeratin 8 is useful for identifying adenocarcinomas with simple epithelium origin. It may also be used to differentiate between lobular (perinuclear staining) and ductal (peripheral staining) breast carcinomas.
Cytokeratin 8 (CK8) is present in single-layer epithelial tissue. CK8 frequently interacts with Cytokeratin 18, and Anti-Cytokeratin 8 is useful for identifying adenocarcinomas with simple epithelium origin. It may also be used to differentiate between lobular (perinuclear staining) and ductal (peripheral staining) breast carcinomas.
Cytokeratin 8 (CK8) is present in single-layer epithelial tissue. CK8 frequently interacts with Cytokeratin 18, and Anti-Cytokeratin 8 is useful for identifying adenocarcinomas with simple epithelium origin. It may also be used to differentiate between lobular (perinuclear staining) and ductal (peripheral staining) breast carcinomas.
Cytokeratin 8 (CK8) is present in single-layer epithelial tissue. CK8 frequently interacts with Cytokeratin 18, and Anti-Cytokeratin 8 is useful for identifying adenocarcinomas with simple epithelium origin. It may also be used to differentiate between lobular (perinuclear staining) and ductal (peripheral staining) breast carcinomas.
Cytokeratin 7 (CK7) is a type II keratin which is present in transitional, ductal, glandular, and biliary duct epithelial cells. Cytokeratin 7 is a useful marker for distinguishing between carcinomas of the lung, breast, endometrium, and urothelia (positive stain) from carcinomas of the colon and prostate (negative stain). Cytokeratin 7 is present is nearly all primary lung adenocarcinomas, and is a useful marker in the differential diagnosis of ovarian neoplasms. Anti-Cytokeratin 7 does not stain intermediate filament.
Cytokeratin 7 (CK7) is a type II keratin which is present in transitional, ductal, glandular, and biliary duct epithelial cells. Cytokeratin 7 is a useful marker for distinguishing between carcinomas of the lung, breast, endometrium, and urothelia (positive stain) from carcinomas of the colon and prostate (negative stain). Cytokeratin 7 is present is nearly all primary lung adenocarcinomas, and is a useful marker in the differential diagnosis of ovarian neoplasms. Anti-Cytokeratin 7 does not stain intermediate filament.
Cytokeratin 7 (CK7) is a type II keratin which is present in transitional, ductal, glandular, and biliary duct epithelial cells. Cytokeratin 7 is a useful marker for distinguishing between carcinomas of the lung, breast, endometrium, and urothelia (positive stain) from carcinomas of the colon and prostate (negative stain). Cytokeratin 7 is present is nearly all primary lung adenocarcinomas, and is a useful marker in the differential diagnosis of ovarian neoplasms. Anti-Cytokeratin 7 does not stain intermediate filament.
Cytokeratin 7 (CK7) is a type II keratin which is present in transitional, ductal, glandular, and biliary duct epithelial cells. Cytokeratin 7 is a useful marker for distinguishing between carcinomas of the lung, breast, endometrium, and urothelia (positive stain) from carcinomas of the colon and prostate (negative stain). Cytokeratin 7 is present is nearly all primary lung adenocarcinomas, and is a useful marker in the differential diagnosis of ovarian neoplasms. Anti-Cytokeratin 7 does not stain intermediate filament.
Cytokeratin 5 dimerizes with Cytokeratin 14 to form the cytoskeleton of basal epithelial cells, while Cytokeratin 6 multimerizes with Cytokeratin 16 and/or 17 in the tongue, oral epithelia and esophagus, hair follicles, and glandular epithelia. Anti-Cytokeratin 5 & 6 rarely stains lung adenocarcinoma, but will produce small foci or scattered staining patterns in these Cytokeratin 5 & 6(+) samples. Cytokeratin 5 & 6 staining is useful for identifying squamous cell carcinoma, and can be used to determine the malignancies of myoepithelial cells in the breast and prostate. Cytokeratin 5 & 6 also rarely stains carcinomas of the breast, colon, and prostate. A panel of antibodies against Cytokeratin 5 & 6, TTF-1, napsin A, p63, SOX2, DSC3, and desmoglein-3 is useful for differentiating lung squamous cell carcinoma from lung adenocarcinoma and large cell carcinoma.
Cytokeratin 5 dimerizes with Cytokeratin 14 to form the cytoskeleton of basal epithelial cells, while Cytokeratin 6 multimerizes with Cytokeratin 16 and/or 17 in the tongue, oral epithelia and esophagus, hair follicles, and glandular epithelia. Anti-Cytokeratin 5 & 6 rarely stains lung adenocarcinoma, but will produce small foci or scattered staining patterns in these Cytokeratin 5 & 6(+) samples. Cytokeratin 5 & 6 staining is useful for identifying squamous cell carcinoma, and can be used to determine the malignancies of myoepithelial cells in the breast and prostate. Cytokeratin 5 & 6 also rarely stains carcinomas of the breast, colon, and prostate. A panel of antibodies against Cytokeratin 5 & 6, TTF-1, napsin A, p63, SOX2, DSC3, and desmoglein-3 is useful for differentiating lung squamous cell carcinoma from lung adenocarcinoma and large cell carcinoma.
Cytokeratin 5 dimerizes with Cytokeratin 14 to form the cytoskeleton of basal epithelial cells, while Cytokeratin 6 multimerizes with Cytokeratin 16 and/or 17 in the tongue, oral epithelia and esophagus, hair follicles, and glandular epithelia. Anti-Cytokeratin 5 & 6 rarely stains lung adenocarcinoma, but will produce small foci or scattered staining patterns in these Cytokeratin 5 & 6(+) samples. Cytokeratin 5 & 6 staining is useful for identifying squamous cell carcinoma, and can be used to determine the malignancies of myoepithelial cells in the breast and prostate. Cytokeratin 5 & 6 also rarely stains carcinomas of the breast, colon, and prostate. A panel of antibodies against Cytokeratin 5 & 6, TTF-1, napsin A, p63, SOX2, DSC3, and desmoglein-3 is useful for differentiating lung squamous cell carcinoma from lung adenocarcinoma and large cell carcinoma.
Cytokeratin 5 dimerizes with Cytokeratin 14 to form the cytoskeleton of basal epithelial cells, while Cytokeratin 6 multimerizes with Cytokeratin 16 and/or 17 in the tongue, oral epithelia and esophagus, hair follicles, and glandular epithelia. Anti-Cytokeratin 5 & 6 rarely stains lung adenocarcinoma, but will produce small foci or scattered staining patterns in these Cytokeratin 5 & 6(+) samples. Cytokeratin 5 & 6 staining is useful for identifying squamous cell carcinoma, and can be used to determine the malignancies of myoepithelial cells in the breast and prostate. Cytokeratin 5 & 6 also rarely stains carcinomas of the breast, colon, and prostate. A panel of antibodies against Cytokeratin 5 & 6, TTF-1, napsin A, p63, SOX2, DSC3, and desmoglein-3 is useful for differentiating lung squamous cell carcinoma from lung adenocarcinoma and large cell carcinoma.
Cytokeratin 20 (CK20) forms intermediate filaments and is normally present in gastric and intestinal epithelium, urothelium, and Merkel cells. Anti-Cytokeratin 20 is used for distinguishing specific types of urinary tract epithelial cells and malignant epithelia. Anti-Cytokeratin 20 stains tissues of the colon, stomach, pancreas, biliary system adenocarcinomas, transitional-cell, mucinous ovarian tumours, and Merkel cell carcinomas. Non-mucinous tumours of the ovary and adenocarcinomas of the breast, lung, endometrium, squamous cell, and small cell type are not stained by Anti-Cytokeratin 20.
Cytokeratin 20 (CK20) forms intermediate filaments and is normally present in gastric and intestinal epithelium, urothelium, and Merkel cells. Anti-Cytokeratin 20 is used for distinguishing specific types of urinary tract epithelial cells and malignant epithelia. Anti-Cytokeratin 20 stains tissues of the colon, stomach, pancreas, biliary system adenocarcinomas, transitional-cell, mucinous ovarian tumours, and Merkel cell carcinomas. Non-mucinous tumours of the ovary and adenocarcinomas of the breast, lung, endometrium, squamous cell, and small cell type are not stained by Anti-Cytokeratin 20.
Cytokeratin 20 (CK20) forms intermediate filaments and is normally present in gastric and intestinal epithelium, urothelium, and Merkel cells. Anti-Cytokeratin 20 is used for distinguishing specific types of urinary tract epithelial cells and malignant epithelia. Anti-Cytokeratin 20 stains tissues of the colon, stomach, pancreas, biliary system adenocarcinomas, transitional-cell, mucinous ovarian tumours, and Merkel cell carcinomas. Non-mucinous tumours of the ovary and adenocarcinomas of the breast, lung, endometrium, squamous cell, and small cell type are not stained by Anti-Cytokeratin 20.
Cytokeratin 20 (CK20) forms intermediate filaments and is normally present in gastric and intestinal epithelium, urothelium, and Merkel cells. Anti-Cytokeratin 20 is used for distinguishing specific types of urinary tract epithelial cells and malignant epithelia. Anti-Cytokeratin 20 stains tissues of the colon, stomach, pancreas, biliary system adenocarcinomas, transitional-cell, mucinous ovarian tumours, and Merkel cell carcinomas. Non-mucinous tumours of the ovary and adenocarcinomas of the breast, lung, endometrium, squamous cell, and small cell type are not stained by Anti-Cytokeratin 20.
Cytokeratin 19 (CK19) forms intermediate filaments found in the intracytoplasmic cytoskeleton of epithelial tissue and provides mechanical support. Anti-Cytokeratin 19 stains epithelia and epithelial malignancies such as carcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Cytokeratin 19 is a useful marker for distinguishing hepatocellular carcinoma from intrahepatic cholangiocarcinoma. This differentiation is improved when stained in combination with Cytokeratin 7, CAM5.2, Ber-EP4/MOC31, Hep-Par1, and TTF1. Cytokeratin 19 staining can also be used to recognize thyroid papillary carcinomas.
Cytokeratin 19 (CK19) forms intermediate filaments found in the intracytoplasmic cytoskeleton of epithelial tissue and provides mechanical support. Anti-Cytokeratin 19 stains epithelia and epithelial malignancies such as carcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Cytokeratin 19 is a useful marker for distinguishing hepatocellular carcinoma from intrahepatic cholangiocarcinoma. This differentiation is improved when stained in combination with Cytokeratin 7, CAM5.2, Ber-EP4/MOC31, Hep-Par1, and TTF1. Cytokeratin 19 staining can also be used to recognize thyroid papillary carcinomas.
Cluster of Differentiation 4 (CD4) is a membrane glycoprotein expressed in T helper cells, monocytes, macrophages, granulocytes, and dendritic cells, and is a receptor of human immunodeficiency virus (HIV). CD4 staining is used for identifying lymphoproliferative disorders. Since the majority of peripheral T-cell lymphomas arise from the T helper cell subset, CD4 expression can be found in most forms of T-cell lymphomas as well as anaplastic large T-cell lymphomas and mycosis fungoides. Since CD4 may be aberrantly expressed in neoplastic T-lymphocytes, a panel of markers may be used to identify such tumours. CD4(+) CD25(+) T-cells are reported to exert immunosuppression, which is commonly observed in various types of cancers, including non-small cell lung cancer and cancers of the breast, prostate, and ovary.
Cluster of Differentiation 4 (CD4) is a membrane glycoprotein expressed in T helper cells, monocytes, macrophages, granulocytes, and dendritic cells, and is a receptor of human immunodeficiency virus (HIV). CD4 staining is used for identifying lymphoproliferative disorders. Since the majority of peripheral T-cell lymphomas arise from the T helper cell subset, CD4 expression can be found in most forms of T-cell lymphomas as well as anaplastic large T-cell lymphomas and mycosis fungoides. Since CD4 may be aberrantly expressed in neoplastic T-lymphocytes, a panel of markers may be used to identify such tumours. CD4(+) CD25(+) T-cells are reported to exert immunosuppression, which is commonly observed in various types of cancers, including non-small cell lung cancer and cancers of the breast, prostate, and ovary.
Cluster of Differentiation 4 (CD4) is a membrane glycoprotein expressed in T helper cells, monocytes, macrophages, granulocytes, and dendritic cells, and is a receptor of human immunodeficiency virus (HIV). CD4 staining is used for identifying lymphoproliferative disorders. Since the majority of peripheral T-cell lymphomas arise from the T helper cell subset, CD4 expression can be found in most forms of T-cell lymphomas as well as anaplastic large T-cell lymphomas and mycosis fungoides. Since CD4 may be aberrantly expressed in neoplastic T-lymphocytes, a panel of markers may be used to identify such tumours. CD4(+) CD25(+) T-cells are reported to exert immunosuppression, which is commonly observed in various types of cancers, including non-small cell lung cancer and cancers of the breast, prostate, and ovary.
Cluster of Differentiation 4 (CD4) is a membrane glycoprotein expressed in T helper cells, monocytes, macrophages, granulocytes, and dendritic cells, and is a receptor of human immunodeficiency virus (HIV). CD4 staining is used for identifying lymphoproliferative disorders. Since the majority of peripheral T-cell lymphomas arise from the T helper cell subset, CD4 expression can be found in most forms of T-cell lymphomas as well as anaplastic large T-cell lymphomas and mycosis fungoides. Since CD4 may be aberrantly expressed in neoplastic T-lymphocytes, a panel of markers may be used to identify such tumours. CD4(+) CD25(+) T-cells are reported to exert immunosuppression, which is commonly observed in various types of cancers, including non-small cell lung cancer and cancers of the breast, prostate, and ovary.
Cluster of Differentiation 34 (CD34) is a transmembrane glycoprotein expressed on hematopoietic stem and progenitor cells, vascular endothelium, embryonic fibroblasts, and rare glial cells in nervous tissue. CD34 is the most used marker for characterizing blasts in leukemia. CD34 is also present in some soft tissue tumours including solitary fibrous tumours and gastrointestinal stromal tumours. Proliferating endothelial cells seem to upregulate CD34 expression. Although specificity is low, Anti-CD34 reacts positively with more than 85% of angiosarcoma and Kaposi’s sarcoma.
Cluster of Differentiation 34 (CD34) is a transmembrane glycoprotein expressed on hematopoietic stem and progenitor cells, vascular endothelium, embryonic fibroblasts, and rare glial cells in nervous tissue. CD34 is the most used marker for characterizing blasts in leukemia. CD34 is also present in some soft tissue tumours including solitary fibrous tumours and gastrointestinal stromal tumours. Proliferating endothelial cells seem to upregulate CD34 expression. Although specificity is low, Anti-CD34 reacts positively with more than 85% of angiosarcoma and Kaposi’s sarcoma.
Cluster of Differentiation 34 (CD34) is a transmembrane glycoprotein expressed on hematopoietic stem and progenitor cells, vascular endothelium, embryonic fibroblasts, and rare glial cells in nervous tissue. CD34 is the most used marker for characterizing blasts in leukemia. CD34 is also present in some soft tissue tumours including solitary fibrous tumours and gastrointestinal stromal tumours. Proliferating endothelial cells seem to upregulate CD34 expression. Although specificity is low, Anti-CD34 reacts positively with more than 85% of angiosarcoma and Kaposi’s sarcoma.
Cluster of Differentiation 34 (CD34) is a transmembrane glycoprotein expressed on hematopoietic stem and progenitor cells, vascular endothelium, embryonic fibroblasts, and rare glial cells in nervous tissue. CD34 is the most used marker for characterizing blasts in leukemia. CD34 is also present in some soft tissue tumours including solitary fibrous tumours and gastrointestinal stromal tumours. Proliferating endothelial cells seem to upregulate CD34 expression. Although specificity is low, Anti-CD34 reacts positively with more than 85% of angiosarcoma and Kaposi’s sarcoma.
CD317, also known as BST2, tetherin, HM1.2 antigen, DAMP-2, is an integral transmembrane glycoprotein which may play a role in pre-B-cell growth, rheumatoid arthritis, and in antiretroviral defense, that blocks release of retrovirus from the cell surface. It is highly expressed on terminally differentiated normal plasmacytoid dendritic cells and some tumor cells, such as multiple myeloma, renal cell carcinoma, and melanoma cells.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
CD317, also known as BST2, tetherin, HM1.2 antigen, DAMP-2, is an integral transmembrane glycoprotein which may play a role in pre-B-cell growth, rheumatoid arthritis, and in antiretroviral defense, that blocks release of retrovirus from the cell surface. It is highly expressed on terminally differentiated normal plasmacytoid dendritic cells and some tumor cells, such as multiple myeloma, renal cell carcinoma, and melanoma cells.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC317
Antibody Isotype:
IgG2a
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Spleen
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
CD317, also known as BST2, tetherin, HM1.2 antigen, DAMP-2, is an integral transmembrane glycoprotein which may play a role in pre-B-cell growth, rheumatoid arthritis, and in antiretroviral defense, that blocks release of retrovirus from the cell surface. It is highly expressed on terminally differentiated normal plasmacytoid dendritic cells and some tumor cells, such as multiple myeloma, renal cell carcinoma, and melanoma cells.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC317
Antibody Isotype:
IgG2a
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Spleen
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
CD317, also known as BST2, tetherin, HM1.2 antigen, DAMP-2, is an integral transmembrane glycoprotein which may play a role in pre-B-cell growth, rheumatoid arthritis, and in antiretroviral defense, that blocks release of retrovirus from the cell surface. It is highly expressed on terminally differentiated normal plasmacytoid dendritic cells and some tumor cells, such as multiple myeloma, renal cell carcinoma, and melanoma cells.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC317
Antibody Isotype:
IgG2a
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Spleen
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 31 (CD31) is present on hematopoietic stem cells (HSCs), and its expression is used to determine the concentration of HSCs in research studies and for bone marrow transplantation. Anti-CD31 is very specific and sensitive for endothelial cells and does not stain non-vascular tumours, therefore CD31 staining is used to recognize the vascular origins of neoplasms.
Cluster of Differentiation 31 (CD31) is present on hematopoietic stem cells (HSCs), and its expression is used to determine the concentration of HSCs in research studies and for bone marrow transplantation. Anti-CD31 is very specific and sensitive for endothelial cells and does not stain non-vascular tumours, therefore CD31 staining is used to recognize the vascular origins of neoplasms.
Cluster of Differentiation 31 (CD31) is present on hematopoietic stem cells (HSCs), and its expression is used to determine the concentration of HSCs in research studies and for bone marrow transplantation. Anti-CD31 is very specific and sensitive for endothelial cells and does not stain non-vascular tumours, therefore CD31 staining is used to recognize the vascular origins of neoplasms.
Cluster of Differentiation 31 (CD31) is present on hematopoietic stem cells (HSCs), and its expression is used to determine the concentration of HSCs in research studies and for bone marrow transplantation. Anti-CD31 is very specific and sensitive for endothelial cells and does not stain non-vascular tumours, therefore CD31 staining is used to recognize the vascular origins of neoplasms.
Cluster of Differentiation 30 (CD30) is a transmembrane cytokine receptor expressed by activated T- and B- cells. It is present on Reed-Sternberg cells in Hodgkin's lymphoma, most anaplastic large cell lymphomas, embryonal carcinomas, and primary cutaneous CD30 positive T-cell lymphoproliferative disorders. B-cell lymphomas are sometimes stained by Anti-CD30. Lymphomas exhibit Golgi zone accentuation when stained with Anti-CD30, while embryonal carcinomas produce membranous stains.
Cluster of Differentiation 30 (CD30) is a transmembrane cytokine receptor expressed by activated T- and B- cells. It is present on Reed-Sternberg cells in Hodgkin's lymphoma, most anaplastic large cell lymphomas, embryonal carcinomas, and primary cutaneous CD30 positive T-cell lymphoproliferative disorders. B-cell lymphomas are sometimes stained by Anti-CD30. Lymphomas exhibit Golgi zone accentuation when stained with Anti-CD30, while embryonal carcinomas produce membranous stains.
Cluster of Differentiation 30 (CD30) is a transmembrane cytokine receptor expressed by activated T- and B- cells. It is present on Reed-Sternberg cells in Hodgkin's lymphoma, most anaplastic large cell lymphomas, embryonal carcinomas, and primary cutaneous CD30 positive T-cell lymphoproliferative disorders. B-cell lymphomas are sometimes stained by Anti-CD30. Lymphomas exhibit Golgi zone accentuation when stained with Anti-CD30, while embryonal carcinomas produce membranous stains.
Cluster of Differentiation 30 (CD30) is a transmembrane cytokine receptor expressed by activated T- and B- cells. It is present on Reed-Sternberg cells in Hodgkin's lymphoma, most anaplastic large cell lymphomas, embryonal carcinomas, and primary cutaneous CD30 positive T-cell lymphoproliferative disorders. B-cell lymphomas are sometimes stained by Anti-CD30. Lymphomas exhibit Golgi zone accentuation when stained with Anti-CD30, while embryonal carcinomas produce membranous stains.
Cluster of Differentiation 3 (CD3) is a T-cell co-receptor expressed by T-cells in thymus, peripheral lymphoid tissue, blood, and bone marrow, as well as activated natural killer cells. CD3 is specifically expressed by T-cells at all stages of development including T-cell lymphomas and leukemias; therefore, it can be used to classify T-cell neoplasms from B-cell and myeloid neoplasms.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 3 (CD3) is a T-cell co-receptor expressed by T-cells in thymus, peripheral lymphoid tissue, blood, and bone marrow, as well as activated natural killer cells. CD3 is specifically expressed by T-cells at all stages of development including T-cell lymphomas and leukemias; therefore, it can be used to classify T-cell neoplasms from B-cell and myeloid neoplasms.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC534
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 3 (CD3) is a T-cell co-receptor expressed by T-cells in thymus, peripheral lymphoid tissue, blood, and bone marrow, as well as activated natural killer cells. CD3 is specifically expressed by T-cells at all stages of development including T-cell lymphomas and leukemias; therefore, it can be used to classify T-cell neoplasms from B-cell and myeloid neoplasms.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC534
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 3 (CD3) is a T-cell co-receptor expressed by T-cells in thymus, peripheral lymphoid tissue, blood, and bone marrow, as well as activated natural killer cells. CD3 is specifically expressed by T-cells at all stages of development including T-cell lymphomas and leukemias; therefore, it can be used to classify T-cell neoplasms from B-cell and myeloid neoplasms.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC534
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 23 (CD23) is found on interleukin-4 activated B-cells, activated macrophages, eosinophils, and follicular dendritic cells, and is a receptor for IgE, an antibody involved in parasitic immunity. CD23 is present on Reed-Sternberg cells in Hodgkin's disease. Follicular dendritic cells and activated B-lymphocytes produce strong staining in germinal centers and weak patterns in mantle zone B-cells. CD23 is helpful in differentiating chronic lymphocytic leukemia from mantle cell leukemia. Small B-cell lymphomas are sometimes positive, while precursor B- and T-lymphomas, myeloid neoplasms, and mature T-cell lymphomas stain negatively with Anti-CD23.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 23 (CD23) is found on interleukin-4 activated B-cells, activated macrophages, eosinophils, and follicular dendritic cells, and is a receptor for IgE, an antibody involved in parasitic immunity. CD23 is present on Reed-Sternberg cells in Hodgkin's disease. Follicular dendritic cells and activated B-lymphocytes produce strong staining in germinal centers and weak patterns in mantle zone B-cells. CD23 is helpful in differentiating chronic lymphocytic leukemia from mantle cell leukemia. Small B-cell lymphomas are sometimes positive, while precursor B- and T-lymphomas, myeloid neoplasms, and mature T-cell lymphomas stain negatively with Anti-CD23.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC023
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Tonsil, Lymph Node, Cll/Sll
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 23 (CD23) is found on interleukin-4 activated B-cells, activated macrophages, eosinophils, and follicular dendritic cells, and is a receptor for IgE, an antibody involved in parasitic immunity. CD23 is present on Reed-Sternberg cells in Hodgkin's disease. Follicular dendritic cells and activated B-lymphocytes produce strong staining in germinal centers and weak patterns in mantle zone B-cells. CD23 is helpful in differentiating chronic lymphocytic leukemia from mantle cell leukemia. Small B-cell lymphomas are sometimes positive, while precursor B- and T-lymphomas, myeloid neoplasms, and mature T-cell lymphomas stain negatively with Anti-CD23.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC023
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Tonsil, Lymph Node, Cll/Sll
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 23 (CD23) is found on interleukin-4 activated B-cells, activated macrophages, eosinophils, and follicular dendritic cells, and is a receptor for IgE, an antibody involved in parasitic immunity. CD23 is present on Reed-Sternberg cells in Hodgkin's disease. Follicular dendritic cells and activated B-lymphocytes produce strong staining in germinal centers and weak patterns in mantle zone B-cells. CD23 is helpful in differentiating chronic lymphocytic leukemia from mantle cell leukemia. Small B-cell lymphomas are sometimes positive, while precursor B- and T-lymphomas, myeloid neoplasms, and mature T-cell lymphomas stain negatively with Anti-CD23.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC023
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Tonsil, Lymph Node, Cll/Sll
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 21 (CD21) is a glycoprotein on the surface of B-cells that is bound by Epstein-Barr virus (EBV) during infection of these cells. CD21 staining is useful for recognizing follicular dendritic cell matrices in normal tonsillar and lymph tissue, and can also stain dendritic cell sarcomas. CD21 is also useful for distinguishing marginal zone lymphoma with follicular involvement from follicular lymphoma with marginal zone differentiation. When used in concert with other B- and T-cell markers, CD21 is valuable for differentiating between nodular lymphocyte-predominant Hodgkin's lymphoma, T-cell/histiocyte-rich B-cell lymphoma, and lymphocyte-rich classic Hodgkin's lymphoma. CD21 staining is useful for recognizing abnormal follicular dendritic cell patterns in angioimmunoblastic T-cell lymphoma and follicular T-cell lymphoma.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 21 (CD21) is a glycoprotein on the surface of B-cells that is bound by Epstein-Barr virus (EBV) during infection of these cells. CD21 staining is useful for recognizing follicular dendritic cell matrices in normal tonsillar and lymph tissue, and can also stain dendritic cell sarcomas. CD21 is also useful for distinguishing marginal zone lymphoma with follicular involvement from follicular lymphoma with marginal zone differentiation. When used in concert with other B- and T-cell markers, CD21 is valuable for differentiating between nodular lymphocyte-predominant Hodgkin's lymphoma, T-cell/histiocyte-rich B-cell lymphoma, and lymphocyte-rich classic Hodgkin's lymphoma. CD21 staining is useful for recognizing abnormal follicular dendritic cell patterns in angioimmunoblastic T-cell lymphoma and follicular T-cell lymphoma.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC533
Antibody Isotype:
IgG2a
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil, Lymph Node
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 21 (CD21) is a glycoprotein on the surface of B-cells that is bound by Epstein-Barr virus (EBV) during infection of these cells. CD21 staining is useful for recognizing follicular dendritic cell matrices in normal tonsillar and lymph tissue, and can also stain dendritic cell sarcomas. CD21 is also useful for distinguishing marginal zone lymphoma with follicular involvement from follicular lymphoma with marginal zone differentiation. When used in concert with other B- and T-cell markers, CD21 is valuable for differentiating between nodular lymphocyte-predominant Hodgkin's lymphoma, T-cell/histiocyte-rich B-cell lymphoma, and lymphocyte-rich classic Hodgkin's lymphoma. CD21 staining is useful for recognizing abnormal follicular dendritic cell patterns in angioimmunoblastic T-cell lymphoma and follicular T-cell lymphoma.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC533
Antibody Isotype:
IgG2a
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil, Lymph Node
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 21 (CD21) is a glycoprotein on the surface of B-cells that is bound by Epstein-Barr virus (EBV) during infection of these cells. CD21 staining is useful for recognizing follicular dendritic cell matrices in normal tonsillar and lymph tissue, and can also stain dendritic cell sarcomas. CD21 is also useful for distinguishing marginal zone lymphoma with follicular involvement from follicular lymphoma with marginal zone differentiation. When used in concert with other B- and T-cell markers, CD21 is valuable for differentiating between nodular lymphocyte-predominant Hodgkin's lymphoma, T-cell/histiocyte-rich B-cell lymphoma, and lymphocyte-rich classic Hodgkin's lymphoma. CD21 staining is useful for recognizing abnormal follicular dendritic cell patterns in angioimmunoblastic T-cell lymphoma and follicular T-cell lymphoma.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC533
Antibody Isotype:
IgG2a
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil, Lymph Node
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation (CD20), also known as B-Lymphocyte Antigen, is a non-glycosylated protein expressed on the surface of normal and malignant B-cells, which functions in chemokine signaling and microenvironmental interactions of B-cells. Anti-CD20 stains a minority of Reed-Sternberg cells with Hodgkin's disease. Since CD20 does not stain T-cell malignancies, it is a very useful marker for B-cell lymphomas. CD20 is also not reactive on non-hematopoietic neoplasms.
Cluster of Differentiation (CD20), also known as B-Lymphocyte Antigen, is a non-glycosylated protein expressed on the surface of normal and malignant B-cells, which functions in chemokine signaling and microenvironmental interactions of B-cells. Anti-CD20 stains a minority of Reed-Sternberg cells with Hodgkin's disease. Since CD20 does not stain T-cell malignancies, it is a very useful marker for B-cell lymphomas. CD20 is also not reactive on non-hematopoietic neoplasms.
Cluster of Differentiation (CD20), also known as B-Lymphocyte Antigen, is a non-glycosylated protein expressed on the surface of normal and malignant B-cells, which functions in chemokine signaling and microenvironmental interactions of B-cells. Anti-CD20 stains a minority of Reed-Sternberg cells with Hodgkin's disease. Since CD20 does not stain T-cell malignancies, it is a very useful marker for B-cell lymphomas. CD20 is also not reactive on non-hematopoietic neoplasms.
Cluster of Differentiation (CD20), also known as B-Lymphocyte Antigen, is a non-glycosylated protein expressed on the surface of normal and malignant B-cells, which functions in chemokine signaling and microenvironmental interactions of B-cells. Anti-CD20 stains a minority of Reed-Sternberg cells with Hodgkin's disease. Since CD20 does not stain T-cell malignancies, it is a very useful marker for B-cell lymphomas. CD20 is also not reactive on non-hematopoietic neoplasms.
Cluster of Differentiation 2 (CD2) is a useful early T-cell lineage restricted antigen that is present in T-cell differentiation. As a pan-T-cell marker, CD2 staining is used for recognizing practically all normal T-cells, but may be deleted in some T-cell neoplasms. Since CD2 is present in most precursor and mature T-cell leukemias and lymphomas, it is useful in the evaluation of lymphoid malignancies. By using CD2 and CD25 staining, the recognition of systemic mastocytosis and mastocytic leukemia is supported.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 2 (CD2) is a useful early T-cell lineage restricted antigen that is present in T-cell differentiation. As a pan-T-cell marker, CD2 staining is used for recognizing practically all normal T-cells, but may be deleted in some T-cell neoplasms. Since CD2 is present in most precursor and mature T-cell leukemias and lymphomas, it is useful in the evaluation of lymphoid malignancies. By using CD2 and CD25 staining, the recognition of systemic mastocytosis and mastocytic leukemia is supported.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC531
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 2 (CD2) is a useful early T-cell lineage restricted antigen that is present in T-cell differentiation. As a pan-T-cell marker, CD2 staining is used for recognizing practically all normal T-cells, but may be deleted in some T-cell neoplasms. Since CD2 is present in most precursor and mature T-cell leukemias and lymphomas, it is useful in the evaluation of lymphoid malignancies. By using CD2 and CD25 staining, the recognition of systemic ma
